Hematopoietic stem cell maintenance in steady-state and inflammation by Fritsch, Kristin
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
Hematopoietic stem cell maintenance in steady-state and inflammation
Fritsch, Kristin
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-150232
Dissertation
Published Version
Originally published at:
Fritsch, Kristin. Hematopoietic stem cell maintenance in steady-state and inflammation. 2017, University
of Zurich, Faculty of Science.
Hematopoietic Stem Cell Maintenance 
in Steady-State and Inflammation 
 
 
 
Dissertation  
zur 
Erlangung der naturwissenschaftlichen Doktorwürde 
(Dr.sc.nat.) 
vorgelegt der 
Mathematisch-naturwissenschaftlichen Fakultät 
der 
Universität Zürich 
von 
Kristin Fritsch 
aus 
Deutschland 
 
 
Promotionskomitee 
Prof. Dr. med. Markus G. Manz (Vorsitz, Leitung der Dissertation) 
Prof. Dr. Sebastian Jessberger 
Prof. Dr. Freddy Radtke 
 
 
 
 
 
Zürich, 2017  
 2 
Table of contents 
 
 
ABBREVIATIONS ...................................................................................................... 3 
SUMMARY ................................................................................................................. 6 
ZUSAMMENFASSUNG ............................................................................................. 8 
INTRODUCTION ...................................................................................................... 11 
Hematopoiesis in steady state ............................................................................... 11 
Hematopoietic stem cells .................................................................................... 13 
The hematopoietic niche ..................................................................................... 15 
Hematopoiesis under inflammatory conditions ...................................................... 17 
Hematopoietic stem cell response to stress ....................................................... 17 
Hematopoietic stem cell niche response to hematopoietic stress ....................... 19 
Engineering of a hematopoietic niche .................................................................... 20 
AIM OF THE THESIS ............................................................................................... 23 
RESEARCH ARTICLE 1 .......................................................................................... 24 
RESEARCH ARTICLE 2 .......................................................................................... 59 
CONTRIBUTIONS .................................................................................................... 78 
DISCUSSION AND OUTLOOK ................................................................................ 84 
CONCLUSIONS ....................................................................................................... 87 
ACKNOWLEDGEMENTS ........................................................................................ 88 
REFERENCE LIST ................................................................................................... 90 
CURRICULUM VITAE .............................................................................................. 97 
 
  
 3 
ABBREVIATIONS 
 
5-FU    5 Fluorouracil 
AGM    aorta-gonadmesonepros region 
AML    Acute myeloid leukemia 
Ang-1    Angiopoietin 1 
BM    Bone marrow 
BrdU    Bromodeoxyuridine 
CAR cells   CXCL12 abundant reticular cells 
CB    Cord blood 
CD    Cluster of differentiation 
cDNA    complementary DNA 
CFSE 5-(and-6)-Carboxyfluorescein Diacetate, Succinimidyl 
Ester 
CFU-E   Colony- forming unit - erythrocyte 
CFU-F   Colony- forming unit – fibroblast 
CFU-G   Colony- forming unit – granulocyte 
CFU-GM   Colony- forming unit – granulucyte macrophage 
CFU-GEMM Colony- forming unit – granulucyte erythrocyte 
macrophage megakaryocyte 
CFU-M   Colony- forming unit – macrophage 
CFU-Mk   Colony- forming unit – megakaryocyte 
c-kit c-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog (Stem cell growth factor receptor) 
CLP    Common lymphoid progenitor cells 
CMP    Common myeloid progenitor cells 
CXCL12   C-X-C motif chemokine ligand 12 (SDF-1) 
DNA    Desoxyribonucleic acid 
EPO    Erythropoietin 
FACS    Fluorescence-activated cell sorting 
FL    Fetal Liver 
Flt3L    FMS-like- tyrosine kinase ligand 
G0    Gap 0 cell cycle phase 
G1    Gap 1 cell cycle phase 
G-CSF   Granulocyte colony stimulating factor  
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GMP    Granulocyte-macrophage progenitor 
GM-CSF   Granulocyte macrophage colony stimulating factor 
H2AX    H2A histone family member X 
H&E    haematoxylin and eosin 
HHLS    Human hemato-lymphoid system 
HSC    Hematopoietic stem cell 
HSPC    Hematopoietic stem and progenitor cell 
IFNα/γ   Interferon alpha/gamma 
IL-6    Interleukin 6 
KI    Knock-in 
LepR    Leptin receptor 
LIC    leukemia-initiating cell 
Lin-    Lineage negative 
LKS    Lin-c-kit+Sca-1+ 
LMPP    Lymphoid-primed multipotent progenitor 
LPS    Lipopolysaccharide 
LT-HSC   Long-term hematopoietic stem cell 
MAPK    Mitogen-activated protein kinase 
MCP1    Monocyte chemotactic protein-1 
M-CSF   Macrophage colony stimulating factor 
MDS    Myelodysplastic syndrome 
MEP    Megakaryocyte-erythrocyte progenitor 
MHC    Major histocompatibility complex 
MLP    Multipotent lymphoid progenitor 
mPCL    Medical-grade polycaprolactone 
MPP    Multipotent progenitor 
MSC    Mesenchymal stromal cell (or Mesenchymal stem cell) 
MyD88   Myeloid differentiation primary response gene 88 
MyelP    Myeloid progenitor 
NAC    N-acetyl-L-cysteine 
NaS    Sodium salicylate 
NBD    NEMO-binding domain peptide 
NK cells   Natural killer cells 
NSG    NOD scid gamma 
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PAMP    Pathogen-associated molecular pattern 
PBS    Phosphate buffered saline 
PRR    Pattern recognition receptor 
RNA    Ribonucleic acid 
ROS    Reactive oxygen species 
Sca-1    Ly6a lymphocyte antigen 6 complex 
SCF    Stem cell factor 
SDF-1α   Stromal cell-derived factor 1 alpha 
SEC    Sinusoidal endothelial cells 
S/G2/M   Synthesis/ Gap2/ Mitosis 
ST-HSC   Short-term hematopoietic stem cell 
Tg    Transgene 
TGF-β   Transforming growth factor- beta 
Tie2 Tyrosine kinase with immunoglobulin-like and EGF-like 
domain 2 (or angiopoietin receptor) 
TIFAB TRAF-interacting protein with forkhead-associated domain 
B 
TLR    Toll-like receptor 
TNF-α   Tumor necrosis factor alpha 
TPO    Thrombopoietin 
TRAF6   TNF receptor associated factor 6 
TRIF    TIR-domain-containing adapter-inducing interferon-β 
Tx    Transplantation 
UC    Umbilical cord 
WAT    White adipose tissue 
Wnt    Wingless oncogene analog 
WT    Wild type 
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SUMMARY 
 
Blood cells in the hematopoietic system are derived from lifelong self-renewing 
hematopoietic stem cells (HSC) in the bone marrow (BM). The two major 
characteristics of HSCs are their ability to self-renew and to generate all lineage cells 
of blood and the immune system throughout the lifespan of an organism. As the 
majority of the mature hematopoietic cells have a relatively short half-life, mature 
blood cells need to be constantly generated by the upstream precursors. 
Nevertheless, in case of hematopoietic stress, such as bleeding or 
infection/inflammation, the hematopoietic system is capable of rapid adaption by 
increasing cellular output in order to meet the higher demand of the respective blood 
cell type production. In case of infection or inflammation, non-hematopoietic and 
hematopoietic cells as immune cells and hematopoietic stem and progenitors cells, 
recognize the invading pathogen by pattern recognition receptors (PRR). Toll-like 
receptors (TLR), a group of PRRs, recognize microbial products derived from 
exogenous pathogens and induce a cell-dependent proliferation, differentiation, 
migration, as well as protein production and secretion in order to generate an efficient 
immune response against invaliding pathogens. Recent findings have indicated that 
not only the peripheral mature immune cells but also HSCs in BM can respond to 
infection by sensing pathogen-associated molecular patterns (PAMPs) through PRRs 
or pro-inflammatory cytokines through respective cytokine receptors.  
We previously showed that in vivo repetitive challenge with lipopolysaccharide 
(LPS), recapitulating gram-negative bacterial infection through Toll-like receptor 4 
(TLR4) stimulation, drives dormant HSCs into proliferation1. Therefore, in one part of 
my thesis, I addressed the consequences for HSC function upon LPS challenge and 
the underlying molecular mechanisms. This study shows that direct activation of 
TLR4 limits the competitive repopulating ability of HSCs via TRIF, but not MYD88-
mediated pathways, and increases divisional history and DNA damage and repair 
responses in HSCs. In vivo pharmacological inhibition of reactive oxygen species 
(ROS) and p38 mitogen-activated protein kinase (MAPK) inhibits LPS-induced HSC 
proliferation and dysfunction, identifying ROS-p38 as the responsible TLR4 
downstream signals. These findings suggest that systemic infection might cause 
accumulation of genetic events in HSCs that eventually even might lead to malignant 
transformation and eventually development of leukemia. 
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Hematopoietic homeostasis is maintained in a specialized microenvironment 
in the BM, the so-called BM HSC niche. The cellular property of hematopoietic stem 
cells (HSCs), i.e., self-renewal and differentiation, is tightly controlled to sustain 
lifelong blood production via extrinsic factors supplied in part by BM niche cells. While 
the cellular and molecular components of the mouse BM niche have been extensively 
studied in experimental animals, little is known about human BM niche components. 
In the second part of my thesis, I took a developmental tissue engineering 
approach that allows to ex vivo generate a human cartilage template with human 
adult BM-derived mesenchymal stromal cells (MSCs), and to in vivo develop human 
bone organs, thereafter called “ossicles” through endochondral ossification, to study 
human BM niche homeostasis. Ex vivo developed ossicles were implanted into 
immune-deficient human cytokine knock-in mice which were transplanted with cord 
blood (CB)-derived human CD34+ cells in order to reconstitute human 
hematopoiesis, following sublethal irradiation. This study indicates that human MSC-
derived ossicles develop a vascular network and a mature trabecular bone-like 
structure with the development of functional human hematopoiesis with phenotypic 
HSCs. This suggests that human ossicles can serve as niche to support human 
hematopoiesis. Furthermore, a successful reengineering of the humanized BM niche 
by overexpressing SDF-1α, a chemokine protein responsible for the maintenance of 
HSCs, shows an increase in functional human HSCs and progenitor engraftment and 
maintenance.  
These findings indicate that bone organs, in vivo developed by adult BM 
MSCs, can support engraftment and maintenance of allogeneic human HSCs and 
hematopoiesis, proving a functional human BM niche. The engineering of a 
heterotrophic human BM niche that is transplantable and genetically re-engineerable 
will serve as a platform that allows to study physiology and pathophysiology of 
healthy and diseased human hematopoiesis in an optimized environment in vivo. 
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ZUSAMMENFASSUNG 
 
Der Ursprung aller Blutzellen im hämatopoetischen System stammt aus sich 
lebenslang selbst-erneuernden hämatopoetischen Stammzellen (HSC) im 
Knochenmark (BM). Die zwei Hauptmerkmale von HSC sind ihre Fähigkeit, sich 
selbst zu erneuern und alle Zelllinien des Blutes und des Immunsystems während 
der Lebensdauer eines Organismus zu erzeugen. Da die meisten reifen 
hämatopoetischen Zellen eine relativ kurze Halbwertszeit aufweisen, müssen reife 
Blutzellen ständig durch die vorgeschalteten Vorläufer erzeugt werden. Bei 
hämatopoetischem Stress, wie Blutungen oder Infektionen / Entzündungen, das 
hämatopoetische System durch Erhöhung der Zellproduktion schnell angepasst 
werden, um den höheren Bedarf der jeweiligen Blutzellen zu erfüllen. Im Falle einer 
Infektion oder Entzündung erkennen nicht-hämatopoetische und hämatopoetische 
Zellen wie Immunzellen und hämatopoetische Stamm- und Vorläuferzellen das 
eindringende Pathogen durch Mustererkennungsrezeptoren (PRR). Toll-like 
Rezeptoren (TLR), eine Gruppe von PRRs, erkennen mikrobielle Produkte aus 
exogenen Pathogenen und induzieren eine zellabhängige Proliferation, 
Differenzierung, Migration sowie Proteinproduktion und Sekretion, um eine effiziente 
Immunantwort gegen eindringende Pathogene zu generieren . Neuste Ergebnisse 
haben gezeigt, dass nicht nur die peripheren reifen Immunzellen, sondern auch HSC 
im BM auf eine Infektion durch Erfassung von Pathogen-assoziierten molekularen 
Mustern (PAMPs) durch PRRs oder proinflammatorische Zytokine durch jeweilige 
Zytokinrezeptoren reagieren können.  
 Wir haben bereits gezeigt, dass eine sich wiederholende in vivo Stimulationen 
mit Lipopolysaccharide (LPS), welches eine gramnegative bakterielle Infektion durch 
Toll-like-Rezeptor 4 (TLR4) Stimulation rekapituliert, die Proliferation von ruhenden 
HSC fördert. In einem Teil meiner Dissertation, habe ich daher die Konsequenzen für 
die HSC-Funktion durch die LPS-Herausforderung und die zugrundeliegenden 
molekularen Mechanismen erforscht. Diese Studie zeigt, dass die direkte Aktivierung 
von TLR4 die konkurrierende Wiederbesiedlungsfähigkeit von HSC über TRIF, aber 
nicht MYD88-vermittelte Signalwege limitiert. Auch erhöht sich durch LPS-Stimulation 
die Proliferationshistorie und DNA-Schädigungs- und Reparaturantworten in HSC. 
Die pharmakologische in vivo Hemmung der reaktiven Sauerstoffspezies (ROS) und 
der p38 Mitogen-aktivierte Proteinkinase (MAPK), hemmt die LPS-induzierte HSC-
Proliferation und Dysfunktion, und identifiziert ROS-p38 als verantwortliche TLR4-
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Downstream-Signale. Diese Ergebnisse deuten darauf hin, dass eine systemische 
Infektion eine Akkumulation von genetischen Ereignissen in HSC verursachen 
könnte, die schließlich sogar zu einer bösartigen Transformation und schließlich zur 
Entwicklung von Leukämie führen könnten. 
 Die HSC Homöostase wird in einer spezialisierten Mikroumgebung im BM 
erzeugt, der sogenannten BM HSC Nische. Die zelluläre Eigenschaft von 
hämatopoetischen Stammzellen (HSC), d.h. Selbsterneuerung und Differenzierung, 
wird streng kontrolliert, um die lebenslange Blutproduktion über extrinsische 
Faktoren, die teilweise von BM-Nischenzellen geliefert werden, zu gewährleisten. 
Während die zellulären und molekularen Komponenten der Maus-BM-Nische 
ausführlich in Tieren experimentell untersucht wurden, ist wenig über die humanen 
BM-Nischenkomponenten bekannt.  
Im zweiten Teil meiner Dissertation benutzte ich eine entwicklungstechnische 
Gewebe Engineering-Methode, die es ermöglicht, ex vivo eine menschliche Knorpel 
Vorlage mit menschlichen erwachsenen, BM-abgeleiteten mesenchymalen 
Stromazellen (MSCs) zu erzeugen und in vivo durch endochondrale Ossifikation in 
menschliche Knochenorgane, sogenannte “Ossicle”, zu entwickeln, um menschliche 
BM Nischenhomöostase zu studieren. Ex vivo entwickelte Ossicle wurden in immun-
defiziente menschliche Zytokin-Knock-in-Mäuse implantiert, und mit Nabelschnurblut 
(CB) -abgeleiteten menschlichen CD34 + -Zellen transplantiert, um die menschliche 
Hämatopoese nach sublethaler Bestrahlung zu rekonstituieren. Diese Studie zeigt, 
dass menschliche MSC-abgeleitete Ossicle ein Maus-Gefäßnetzwerk und eine reife 
trabekuläre Knochen-ähnliche Struktur bilden und eine funktionelle menschliche 
Hämatopoese mit phänotypischen HSC entwickeln. Dies lässt vermuten, dass 
menschliche Ossicle als Nische zur Unterstützung der menschlichen Hämatopoese 
dienen können. Darüber hinaus zeigt eine erfolgreiche Rekonstruierung der 
humanisierten BM-Nische durch die Überexpression von SDF-1α, einem Chemokin-
Protein, das für die Instandhaltung von HSCs verantwortlich ist, eine Zunahme der 
Erhaltung von funktionellen humanen HSC und Vorläuferzellen.  
Diese Ergebnisse deuten darauf hin, dass Knochenorgane, die in vivo von 
erwachsenen BM MSC entwickelt wurden, allogene humane HSCs und 
Hämatopoese unterstützen können, welches die funktionalität zeigt. Die Entwicklung 
einer heterotrophen humanen BM-Nische, die transplantierbar und gentechnisch 
rekonstruierbar ist, dient als Plattform, die es ermöglicht, die Physiologie und 
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Pathophysiologie einer gesunden und kranken menschlichen Hämatopoese in einer 
optimierten Umgebung in vivo zu untersuchen. 
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INTRODUCTION 
 
Hematopoiesis in steady state 
 
Hematopoiesis is a lifelong dynamic process by which all cells of the blood system 
are produced from a small population of hematopoietic stem cells (HSCs) in a 
hierarchical manner. HSCs with lifelong self-renewal ability give rise to progenitor 
cells that differentiate into lineage-committed progenitors and ultimately produce all 
lineages of mature blood cells, including red blood cells, platelets, leukocytes of 
myeloid lineage, lymphoid lineage and dendritic cell populations2-4 (Figure 1). As 
most mature cells have a limited lifespan, they have to be replenished by HSC-
derived cells to maintain tissue homeostasis throughout the lifetime of an organism. 
In adult humans the bone marrow tissue is about 3 kg, with approximately 0.8 – 1.5 x 
1012 bone marrow cells, releasing each day 2.2 x 1011 red blood cells, 0.45 – 1.2 x 
1011 neutrophils and 1 – 1.75 x 1011 platelets that have to be replaced by the 
hematopoietic system5-7. Furthermore, hematopoiesis is tightly controlled by cell-
intrinsic (epigenetic and transcriptional programs) and cell-extrinsic factors (growth 
factors, cytokines, hormones, supporting cell types in the bone marrow). Most of our 
understanding of physiology of hematopoiesis comes from studies in mice. To also 
gain mechanistic insight in human hematopoiesis the development of humanized 
mouse models might be of high value. 
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Figure 1 Hierarchy within the mouse and human hematopoietic system. 
The hematopoietic system is a hierarchy maintained by self-renewing hematopoietic 
stem cells (HSCs). In mouse, HSCs can be subdivided based on their ability to 
sustain mature blood cells in long-term and short-term HSCs (LT-HSC and ST-HSC). 
HSCs give rise to multiple types of progenitors which have enormous proliferative 
potential but limited self-renewal capability, e.g. multipotent progenitors (MPP), 
lymphoid-primed multipotent progenitors (LMPPs, in humans: MLP), common 
lymphoid progenitors (CLPs), common myeloid progenitors (CMPs), granulocyte–
macrophage progenitors (GMPs), megakaryocyte–erythrocyte progenitors (MEPs). 
Finally, on the bottom of the hierarchy are mature hematpoietic cells of different 
lineages that do not self-renew or have limited ability thereof and are continously 
replenished by upstream progenitors. NK-cells, natural killer cells. (Based on 
Doulatov et. al., Cell Stem Cell 2012) 
 
 
 
 
 
 
 13 
Hematopoietic stem cells 
 
The existence of cells that are characterized by loss of pluripotency but with self-
renewal capacity and a differentiation ability restricted to hematopoietic tissue was 
first demonstrated by Till and McCulloch in 19608. They showed that cells from the 
BM have the ability to self-renew while at the same time differentiate into multiple 
lineages. 
In vertebrates, HSCs are generated during embryonic development. The first wave of 
mouse HSCs precursors of embryonic origin emerge in the yolk sac, starting from 
embryonic day (E) 7.5 and initiate embryonic red blood cell production. It was shown 
that these primitive HSCs were multipotent and capable of long-term reconstitution at 
E10 in the aorta-gonadmesonepros region (AGM) and the placenta9,10. Further 
development of HSCs takes place in the fetal liver (FL) through the expression of 
MHC class I and CD4511. During this stage HSCs are largely cycling and undergoing 
symmetric cell divisions. HSC generation is completed by E14 (so called definitive 
HSCs) and HSCs start to migrate to thymus, spleen, and further to the BM where 
they reside during adult hematopoiesis in a relatively quiescent state. 
  The multipotent progenitor pool is heterogeneous and can be separated into 
quiescent long-term self-renewing HSC (LT-HSC) with an inactive replication 
machinery and low metabolism; transiently active self-renewing HSC (short-term 
HSC, ST-HSC) with an active replication machinery and low metabolism; and non-
self-renewing multipotent progenitors (MPP), with active replication machinery and 
active metabolism12. Studies indicate that most of the mature cells are derived 
primarily from short-term HSCs (ST-HSCs)13. This suggests that steady-state 
hematopoiesis in mouse is primarily sustained by hematopoietic progenitors (20-38% 
in cell cycle) rather than by the HSCs themself13-15. To study HSC behavior in vivo, it 
is necessary to isolate mouse HSCs from total BM cells to high purity. They can be 
phenotypically distinguished from more differentiated progenitors and mature cells by 
expression of their surface markers. In mouse, LT-HSCs are defined by their 
expression of Lin-Sca1+Kit+CD34-CD150+CD48-. They occur at frequencies of 
about 0,005% among total BM cells. In contrast, phenotypic human HSCs have been 
defined by the expression of Lin-CD34+CD38-CD90+CD45RA-16. It was shown that 
0.2% of human CD34+ cells are circulating in the peripheral blood and 1,8% are 
present in the adult human BM17. Better defined HSCs (Lin-CD34+CD38-
CD90+CD45RA+) have a frequency of 0.01 – 0.2 % within BM Mononuclear cells4,18. 
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HSCs replenish hundreds of billions of blood cells daily while they self-renew to 
maintain themselves over the lifetime of the organism. The self-renewal capability of 
HSCs is experimentally defined by their ability to reconstitute the entire blood system 
upon transplantation into a lethally irradiated recipient19. The frequency of HSCs in 
mice is less than 2 per 108 BM cells, which means approximately 11000 – 22000 
HSCs/mouse. Interestingly, in humans the estimated number of HSCs is of the same 
order than in mice20. However, this is under debate (Nombela-Arrieta and Manz, 
submitted). 
In steady-state HSCs are maintained in a quiescent or dormant state in the BM. The 
cell cycle activity of HSCs over the lifetime is equally dynamic and reflects the needs 
of the organism at any given time (Figure 2). Only around 5-10% of total HSCs are in 
cell cycle (reviewed in 21) and 90-95% of HSCs are dormant (G0 phase of cell cycle), 
which suggests that only a few HSC clones give rise to mature blood cells at any 
time22,23,13,24.  
 
Figure 2 Dynamic activities of HSCs. 
In order to preserve lifelong hematopoiesis, HSCs are mostly quiescent (90-95% of 
total HSCs). To maintain the stem cell pool they undergo symmetric cell divisions to 
self-renew, meaning HSCs produce daughter cells identical to them. At the same 
time 5-10% undergo asymmetric cell division to differentiate and generate more 
mature and specialized blood cells. 
 
Nevertheless, it is postulated that quiescent HSCs contribute to the hematopoiesis 
when the proliferative capacity of the active ST-HSC clone is exhausted. Our group 
has shown that dormant HSCs divide only once every 39 days, while previous 
studies indicate that dormant HSCs divide only once every 145d or more1,25. These 
contradictions might arise from technical issues. Several cytokines like interferon 
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(IFN)α26, IFNγ27, granulocyte colony stimulating factor (G-CSF)28 and TPO29 were 
shown to induce activation of dormant HSCs. The balancing act between 
proliferation, self-renewal, quiescence and differentiation is a complex interplay 
between cell-extrinsic (i.e., transforming growth factor-β (TGF-β), Wnt, Hedgehog, 
and Notch) and cell-intrinsic regulatory pathways (i.e., cell cycle regulators and the 
PI3-kinase signaling pathway) (reviewed in21). A dysregulation of these processes 
might transform HSCs and progenitors into disease-initiating leukemic stem cells 
(LIC) and cause BM failure or Leukemia.  
 
The hematopoietic niche 
 
In 1978, R. Schofield proposed the concept of the stem cell niche30. He suggested 
that HSCs reside within a distinct threedimensional structure within a specific 
anatomic location in the BM, that is responsible for their regulation. Since this 
concept, various kinds of specific cells have been identified which regulate HSC self-
renewal, differentiation and quiescence. 
The bone marrow niche cells consists of hematopoietic (macrophages31,32 and 
megakaryocytes33,34) and non-hematopoietic cells (adipocytes35, 
osteoblast/osteoclast cells36-39, endothelial cells40 41, Schwann cells42, as well as 
specialized stromal cells as for example Nestin-positive mesenchymal stromal cells 
(MSCs)43, CXCL12 abundant reticular cells (CARs)44,45, and leptin receptor-positive 
cells (LepR+ cells)45). These BM cells build the so-called BM-niche that directly or 
indirectly regulates HSC self-renewal, differentiation and localization. Furthermore 
the BM niche maintains the quiescent state of HSCs, which is essential in preserving 
their self-renewal capability. The HSC niche was proposed as a regulatory unit that 
limits the entry of HSCs into the cell cycle, thereby protecting them from exhaustion 
or from errors in DNA replication. 
  The interface of bone and bone marrow is known as the endosteum. A layer of 
bone-lining cells that can differentiate into bone-forming osteoblasts and bone-
resorbing osteoclasts cover the endosteal surface. Arteries carry oxygen, nutrients, 
and hematopoietic growth factors into the bone marrow and are surrounded by 
Nestin+ MSCs. Sinusoids are specialized venules that form a reticular network of 
fenestrated vessels that allow cells to pass in and out of the circulation. Sinusoids are 
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often associated with megakaryocytes, reticular cells producing the chemokine 
CXCL12, and mesenchymal progenitors (LeptR+ MSCs). 
 
 
Figure 3 Illustration of the BM HSC niche. 
Previously reported niche cells are depicted. The BM niche is composed of several 
different cell populations that contribute to the regulation of hematopoiesis. HSC, 
hematopoietic stem cells; CAR cell, CXCL12 abundant reticular cell; MSC, 
mesenchymal stromal cell; LepR, Leptin receptor. 
 
 
Although the exact location of HSCs is still under debate, it is now generally accepted 
that adult HSCs localize primarily close to or in direct contact with the sinusoidal 
perivascular regions within the trabecular bone marrow cavities46-48 and not in 
endosteal or osteoblastic niche. Several cellular components have been suggested 
to comprise the endosteal niches; these include osteoblasts, osteoclasts, 
macrophages, sympathetic neurons and vascular endothelial-cadherin+ sinusoidal 
endothelial cells (SECs)49. By contrast, perivascular niches are located more 
centrally in the BM cavities and contain endothelial cells, Nestin+ Mesenchymal 
stromal cells (MSC), Leptin receptor + perivascular stromal cells, Swann cells, CXC-
chemokine ligand 12 (CXCL12)-abundant reticular (CAR) cells, reticular cells and 
megakaryocytes50. The BM HSC niche has been shown to express factors that are 
essential for HSC maintenance and localization, such as thrombopoietin (TPO), 
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Angiopoietin (Ang)-1, CXC-chemokine ligand 12 (CXCL12) and stem cell factor 
(SCF). For example, Ang-1 is expressed and secreted by osteoblasts, and interacts 
with Tie2, a tyrosine kinase receptor, that is expressed on quiescent LT-HSCs, to 
enhance the ability of HSCs to become quiescent39.  
  Comparatively little is known about the cellular and molecular components of the 
human BM niche. Some studies showed that HSCs expand in vitro when co-cultured 
with human endothelial cells or MSCs, suggesting that human HSCs might be 
supported by vascular niches51. In contrast, immunohistochemistry of human BM 
indicates that human HSCs preferentially localize to the trabecular areas of the BM52. 
As in mice these areas contain Nestin+ MSCs, Endothelial cells, osteoblasts and 
macrophages53,54. Nevertheless, the knowledge gained from mouse studies cannot 
be translated to humans, because of the fundamental differences in immune function 
that exist between species. It has been noticed that altering the murine environment 
in favor of human hematopoiesis, by replacing mouse cytokines with their human 
counterparts, is beneficial to the output of human HSCs and differentiated cells. 
Therefore over the last decade, researchers put a lot of effort to develop humanized 
mice models in order to study human healthy and malignant hematopoiesis (reviewed 
in55). 
 
Hematopoiesis under inflammatory conditions 
 
During infection, immune cells are recruited to the local site of infection and 
consumed upon activation during the immune response against the invading 
pathogens56,57. Thus, the short-lived immune cells need to be subsequently 
replenished by upstream hematopoietic stem and progenitor cells (HSPCs) to 
reestablish homeostasis of the hemato-lymphoid system during and after the 
infection ceases. Inflammatory response protects the body from infection and injury 
but can itself become dysregulated.  
Hematopoietic stem cell response to stress 
 
Hematopoietic stress such as bleeding and infection can lead to demand-adopted 
hematopoiesis. Given the fact that HSCs are mostly in cell cycle quiescence (G0), 
understanding the activation and contribution of HSCs to hematopoietic homeostasis 
during inflammation is becoming a major focus of research in the field3,58. Recent 
findings have indicated that not only mature immune cells, but also HSPCs can 
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respond to infection by directly sensing pathogen-associated molecular patterns 
(PAMPs) through respective pattern recognition receptors (PRR)59-61 or by detecting 
via respective cytokine receptors, pro-inflammatory cytokines, released by activated 
immune cells during infection26,27,62. Initiation of an inflammatory response during an 
infection involves, amongst others, one family of receptors, the toll-like receptors 
(TLRs). For example, TLR4, which senses lipopolysaccharide (LPS) and TLR2, 
which senses bacterial lipoproteins. Our group has previously shown that repetitive 
injection of LPS drives quiescent HSCs into cell cycle and increases their turn-over 
from 1 division within 39 days during steady-state to 2-4 divisions within 3 weeks 
during LPS challenge1. However, whether this is a direct or indirect action of LPS on 
TLR expressing HSCs has not been elucidated. Upon TLR stimulation HSCs are 
shown to secrete pro-inflammatory cytokines, e.g. IL-6, TGF-β, TNF-α and 
granulocyte-macrophage colony-stimulating factor (GM-CSF) to promote 
myelopoiesis63. Since HSCs also express a broad spectrum of inflammatory 
cytokine/chemokine receptors they can detect pro-inflammatory signals, released by 
activated immune cells or the BM niche cells, in response to stress (e.g. IFN-α/γ). 
Also, studies show that cytokines produced by immune cells in response to viral or 
bacterial infection, such as IFN-α and IFN-γ can activate quiescent HSCs 26,27,62. 
It has been shown that a chronic infection can impair HSC function and cause BM 
failure27,64. In humans, recent population-based epidemiological studies have 
demonstrated that a previous history of infectious and autoimmune disease is 
associated with an increased risk for acute myeloid leukemia (AML) or 
myelodysplastic syndromes (MDS)65,66. This suggests that chronic inflammation, 
which induces proliferation of dormant HSCs, and thus increases their divisional 
history might increase accumulation of genetic alterations. In addition an SNV 
analysis of hematopoietic stem cells of healthy individuals from newborn until the age 
of 70 shows an accumulation of mutations with increasing age 67. Surprisingly, the 
number of detected mutations in healthy adults were similar to the once detected in 
AML patients of the same age. Other studies indicate that 83% of blood-specific 
mutations, from healthy individuals with advanced age, were from 19 leukemia and/or 
lymphoma-associated genes 68. This data suggests that self-renewing HSCs 
accumulate background mutations as a function of age. 
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Hematopoietic stem cell niche response to hematopoietic stress 
 
It has been shown that not only hematopoietic cells express TLRs, but also 
endothelial cells69,70 and MSC populations, including nestin+ MSCs and CAR cells71 
and thereby might contribute to the innate immune response (Figure 4). TLR 
activation of MSCs not only leads to proliferation, differentiation and tissue 
regeneration 72-74 of themselves but also to the regulation of proliferation and 
differentiation of HSPCs75,76.  
For example, in vitro studies show that LPS induced TLR4 activation on MSCs leads 
to the production of G-CSF, GM-CSF, M-CSF, IL-6 and IL-1176. In vivo studies 
suggest that BM endothelial cells as well as MSCs produce monocyte chemotactic 
protein-1 (MCP1) and promote monocyte migration75. Moreover, a direct LPS - TLR4 
activation in endothelial cells leads to the production of G-CSF, which induces the 
recruitment of neutrophils to infectious sites and in parallel induces granulocyte 
differentiation and survival in order to replenish rapidly consumed neutrophils 70,77,78.  
 
Figure 4 Illustration of the BM HSC niche during inflammatory stimulus. 
Figure summarizes previously reported studies. Hematopoietic and non-hematopietic 
cells are activated in direct and indirect fashion during inflammation. HSC, 
hematopoietic stem cells; CAR cell, CXCL12 abundant reticular cell; MSC, 
mesenchymal stromal cell; LPS, Lipopolysaccharid; TLR, Toll-like receptor; IFN-α/γ, 
interferon-alpha/gamma; M-CSF, Macrophage colony-stimulating factor. 
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The BM niche can be regulated by extrinsic factors, e.g. inflammatory cytokines. In 
detail, G-CSF, which is often induced during infection, leads to an expansion of CAR 
cells and suppresses mature osteoblasts71 and CXCL12 expression in multiple 
stromal populations, e.g. endothelial cells79,80. Furthermore, Tumor necrosis factor-α 
(TNF-α), a proinflammatory cytokine, leads to an increased Notch activation on 
HSCs. Several studies suggest that IL-1 and TNF-α induce GM-CSF production in 
endothelial cells81,82. IFN-γ released from Cytotoxic T cells promotes the IL-6 
production in MSCs and leads to an activation of hematopoietic progenitors83. 
Together, these results demonstrate that the BM plays an important role in 
hematopoietic regulation during inflammation.  
 
Engineering of a hematopoietic niche 
 
The BM niche cells provide survival and maintenance signals to HSCs as well as 
leukemia initiating cells (LICs), which can initiate, propagate, and maintain bulk 
leukemia 84. A dysregulation of these signals results in abnormal differentiation and 
proliferation of HSCs and LICs. There is so far no good model to maintain human 
HSCs and LICs in vitro. It had been a long standing question of what cells can 
establish a hematopoietic microenvironment. Besides the hematopoietic system there 
are also other cells in the BM that can give rise to multilineage cells while retaining 
the ability to self-renew. Friedenstein and coworkers showed that cells from the BM 
can form fibroblastoid colonies (CFU-F). Furthermore these cells can be separated 
by their ability to adhere to plastic85. Later on it was found that these cells are stem 
cells that can differentiate into osteogenic, adipogenic, chondrogenic and myogenic 
mesenchymal lineages in vitro86-92 and are therefore called mesenchymal stem cells. 
In some literature mesenchymal stem cells are also called mesenchymal stromal 
cells because for a long time the self-renewal and differentiation ability of these cells 
could be only confirmed in vitro. Kuznetsov et al.93, could show for the first time that 
mesenchymal stem cells when implanted into immunodeficient mice, can form bone. 
Some Years later, it was shown that not all cells that adhere to culture plastic have 
self-renewal and differentiation capacity in vivo94. Therefore, they are rather restricted 
to be called Mesenchymal Stromal Cells (MSCs). MSCs are able to differentiate into 
chondrocytes through a process that is called endochondral ossification, and to form 
bone marrow microenvironment in vivo95.  Additionally, in vitro maturation 
 21 
(chondrogenic differentiation) of human BM-derived MSCs resulted in an accelerated 
formation of larger bone tissue in vivo96. Several studies have suggested that upon 
subcutaneous implantation of mouse or human MSCs into immune-deficient mice 
these cells are able to form a supportive bone marrow cavity through a vascularized 
cartilage intermediate which was replaced by hematopoietic tissue and bone which 
can attract and support murine hematopoiesis93,97-99. Nevertheless, there is a lack of 
in vivo models that can recapitulate the complexity of human BM environment to 
support normal and malignant hematopoiesis. Thus, the current xenotransplant 
mouse models are not able to reproduce the physiological interactions between 
HSCs and a human BM microenvironment as human HSCs are engrafted in a mouse 
BM microenvironment. A recent study has shown that when comparing MSC from 
different tissues such as BM, white adipose tissue (WAT), umbilical cord (UC) and 
skin, only BM-derived MSCs are able to form a bone marrow cavity through a 
vascularized cartilage intermediate100. Also, this human derived hematopoietic niche 
could home and maintain murine long-term HSCs as well as human HSCs defined as 
CD34+CD38-CD90+CD45RA+ after cord blood transplantation. Interestingly, the 
human HSCs that are maintained in the ectopic niche are functional as shown by 
serial transplantation101. Other work by Chen et al.102 suggested a model of an 
ectopic human extramedullary BM that can be engrafted with human normal and 
leukemic cells. Furthermore, they showed the flexibility of this model by genetical 
manipulation through knock down of hypoxia-inducible factor 1α in MSCs, which 
leads to a significant reduction of human leukemic cell engraftment. However, there 
is no evidence that the human MSCs undergo endochondral ossification in mice, 
which is required for a functional niche formation97. In addition, Holzapfel at al.103 
developed an engineered humanized bone construct by seeding MSCs on a tubular 
medical-grade polycaprolactone (mPCL) scaffold followed by a culture in a rotating 
bioreactor before implanting it into NSG mice. By inducing differentiation of MSC in 
vitro already they were able to recapitulate morphological features and biological 
functions of a human HSC niche. Although they show that human HSC and 
progenitors engraft predominantly within the humanized bone environment, there is a 
lack of functional data in their studies. MSCs are not only present in the BM but also 
in adipose tissue, umbilical cord, placenta, amniotic fluid, dental pulp, skeletal 
muscle, tendons, and synovial membrane104. Nevertheless, Reinisch et al. could 
show that only MSCs from the BM are able to form a bone cavity that can maintain 
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human healthy and malignant cells when implanted in NSG mice100,101. Most of the 
recent studies do not or only in a small amount show the mineralization of the newly 
formed tissue, which does not mimic a fully regenerated bone organ. These 
limitations could be overcome though the establishment of a tissue engineering 
protocol where human adult BM-derived mesenchymal stromal cells (MSCs) are 
differentiated ex vivo into hypertrophic cartilage, and, upon in vivo implantation into 
immunodeficient mice, develop to a fully mature bone organ via endochondral 
ossification (Figure 5).  
 
Figure 5 Engineering of heterotopic human niches in a xenograft mouse model.  
Illustration of in vitro and in vivo engineering of a human bone marrow niche. (From 
Theocharides, Rongvaux, Fritsch, Flavell and Manz, Hematologica, 2016) 
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AIM OF THE THESIS 
HSCs and Inflammation 
It remains exclusive how the primitive hematopoietic stem and progenitor cells 
(HSPCs) react to inflammatory-associated molecules and integrate danger signals to 
enhance and sustain blood production, and how these impact on HSPC function. 
Therefore, it is important to understand the effects of (chronic) inflammatory stimuli 
on HSC homeostasis and pathogenesis. These questions where addressed by 
setting the following aim: 
Aim 1: Effect of bacterial infection on HSCs 
Here we first dissected whether the action of LPS on HSCs is a direct or an indirect 
effect. Further, we wanted to analyze downstream TLR4 signaling and finally show 
the impact of chronic inflammation on the HSC function.  
Modelling Human HSC Environment (Niche)  
Most of the findings about the HSC niche come from mouse studies, as there is no 
good model to study human HSCs in their native environment. To overcome these 
limitations, we established a tissue engineering protocol where human adult BM-
derived mesenchymal stromal cells (MSCs) are ex vivo differentiated into 
hypertrophic cartilage, and, upon in vivo implantation into immunodeficient mice, 
develop into a fully mature bone organ via endochondral ossification. With this model 
we addressed the following aims: 
Aim 2: Engineering a human BM niche to maintain human HSC function 
We generated human ossicles and tested if they sustain robust hematopoietic 
production and long term maintenance of human HSCs in immunodeficient animals 
with a human hemato-lymphoid system (HHLS).   
Aim 3: Reengineering a human BM niche to study human HSC niche factors 
To characterize the human HSC maintenance genes, we genetically modified human 
MSC using overexpression in vitro, we over expressed SDF-1α, a human HSC 
maintenance gene, in the ossicle to study the effect of the overexpression on human 
HSC function.   
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Summary 
Bacterial infection leads to consumption of short-lived hematopoietic innate immune 
effector cells, which need to be replenished from hematopoietic stem and progenitor 
cells (HSPCs). HSPCs express various pattern recognition receptors, such as Toll-
like receptors (TLRs), the ligation of which induces their mobilization, cytokine 
production and myeloid differentiation. However, it remains unclear how TLR 
activation impacts on most upstream, self-renewing HSC. Here, we show that TLR4 
stimulation with lipopolysaccharide (LPS), recapitulating a systemic gram-negative 
bacterial infection, directly induces proliferation of dormant HSCs in vivo. Sustained 
exposure to LPS causes genotoxic stress in HSCs and impairs their competitive 
repopulation activity via activation of TLR4-TRIF-ROS-p38-, but not MyD88-
signalling. This process can be inhibited pharmacologically without preventing 
emergency granulopoiesis. While direct TLR4 activation on HSCs might be beneficial 
to fight acute infection, our findings demonstrate that prolonged signaling has 
detrimental effects on HSCs, which possibly might add to chronic inflammation-
associated malignant HSPCs transformation. 
 
Highlights 
 Direct TLR4 activation on HSCs induces HSC cycling 
 Sustained TLR4 activation on HSC impairs their competitive repopulating 
ability 
 TLR4 stimulation causes genotoxic stress in HSCs via ROS-p38 
 Inhibition of TLR4-TRIF-ROS-p38 signalling prevents LPS-induced HSC 
dysfunction 
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Introduction 
Hematopoietic homeostasis is maintained by hematopoietic stem cells (HSCs) that 
produce all blood cells through intermediate, subsequently lineage-committed 
progenitors4. In contrast to highly proliferating progenitors, a significant fraction of 
HSCs do not contribute to hematopoiesis in steady-state and are in quiescence with 
low metabolic activity, a presumably “safeguard” mechanism to protect HSCs from 
genotoxic reagents and maintain integrity of HSC function3,13. Self-renewal and 
differentiation of HSC are tightly regulated by intrinsic and extrinsic factors, and loss 
of this regulation leads to hematopoietic aplasia or neoplasia, respectively105. HSC 
function is preserved in a bone marrow (BM) microenvironment, referred to as 
“niche”, in which various type of hematopoietic and non-hematopoietic cells express 
vital factors for HSC homeostasis106. 
During hematopoietic stress such as infection and inflammation, where short-
lived mature hematopoietic immune effector cells are activated and consumed, 
HSPCs in the BM need to tailor their cellular output to meet the enhanced demand of 
blood production. To this end, they need to integrate respective signals, ultimately 
stemming via various signalling cascades from the peripheral sites of inflammation. 
Recent findings have proposed two possible, not mutually exclusive regulatory 
mechanisms of HSPC response during systemic bacterial or viral infections: a.) a 
cytokine-mediated mechanism in which pro-inflammatory cytokines are secreted at 
peripheral, immune active sites and/or locally in the BM, and induce proliferation of 
HSPCs via their respective cytokine receptors and the downstream signalling 
cascades26,27,58,62,107,108; b.) a direct sensing mechanism, in which HSPCs themselves 
recognize pathogen-associated molecule patterns (PAMPs) via the respective pattern 
recognition receptors (PRRs), such as Toll-like receptors (TLRs), and increase their 
proliferation, differentiation and migration59-61,109. Indeed, as a combination of both 
mechanisms, a recent study revealed that upon direct TLR activation, HSPCs are 
capable of producing an array of pro-inflammatory cytokines, which, likely in a 
paracrine, self-sustaining manner, enhance proliferation and myeloid differentiation 
under neutropenic conditions in vivo63. 
However, it remained thus far an unresolved fundamental question, if most 
upstream, bona fide long-term, self-renewing HSCs are able to directly sense PAMPs 
and, if so, what would be the consequences for HSC function. We here set out to 
determine this by applying in vivo lipopolysaccharide (LPS), a conserved 
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paradigmatic gram-negative bacterial pattern in context of signalling deficiencies for 
LPS through its cognate receptor TLR4, and the respective downstream adapter 
molecules MyD88 and TRIF.   
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Results 
Systemic LPS application enhances HSCs proliferation directly via TLR4 
It was shown that HSPCs (Lin-c-Kit+Sca-1+, thereafter called LKS, or LKS CD135-) 
express TLR459,63, but it remained unclear if long-term HSCs express TLR4. In 
agreement with a recent report109, we found that highly enriched HSC cell 
populations (LKS CD34-CD150+) that contain long-term, multilineage repopulating 
cells with a 25% purity110, uniformly express the TLR4/MD-2 complex at levels 
comparable to or higher than multipotent and myeloid committed hematopoietic 
progenitor cells (Figure S1A and S1B). Moreover, we demonstrate that mRNA of 
TLR4 and genes such as MYD88 (myeloid differentiation primary response 88) and 
TRIF (also called TICAM-1), involved in respective TLR4 downstream signaling, are 
higher expressed in HSC than in all other cell populations tested (Figure S1C). By 
applying single cell divisional tracking and subsequent evaluation of biological HSC 
read out, i.e., self-renewal and multi-lineage reconstitution, we previously 
demonstrated that dormant HSCs are recruited to proliferation upon systemic LPS 
injections1. To extend these findings, WT mice were treated for two weeks with BrdU 
(5-bromo-2’-deoxyuridine) to label DNA of dividing cells111, and were subsequently 
i.p. injected with PBS or 35 μg LPS every other day for 2 or 4 times to determine 
BrdU retention or loss upon proliferation (Figure 1A). In PBS-treated animals, almost 
all HSC (LKS CD34-CD150+) in BM retained the BrdU label over the two week-
chasing period, indicating their quiescence over this period of time. In contrast to this 
and consistent with our previous findings1, two and four-time systemic LPS injections 
lead to significantly decreased BrdU retention in HSC, thus demonstrating directly or 
indirectly LPS-induced proliferation (Figure 1B). While multipotent progenitors (MPP, 
LKS CD34+), LKS, and myeloid progenitors (Lin-c-Kit+Sca-1-, thereafter called LK) 
proliferated already in the PBS control group, proliferation was further enhanced 
upon LPS application as evidenced by loss of the BrdU label (Figure 1B). 
As increased proliferation renders cells more sensitive to anti-proliferative 
chemotherapeutic drugs, we tested if LPS-induced HSPC proliferation would lead to 
higher hematopoietic toxicity of otherwise sub-lethal doses of 5-FU (5-fluorouracil). 
Indeed, immediate LPS pre-treatment on day 1 and 3 before application of two times 
150 mg/kg 5-FU, resulted in significantly higher mortality, suggesting LPS-enhanced 
proliferation and subsequent 5-FU mediated death of functional HSPCs (Figure 1C). 
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This was not observed in animals pre-treated with LPS on days -7 and -5 prior to 5-
FU, indicating that LPS-induced HSPC cycling is of short duration. 
Both hematopoietic and non-hematopoietic cells such as endothelial cells78 or 
mesenchymal stromal cells75 express functional TLR458. To test the contribution of 
hematopoietic cell-expressed TLR4 to HSC proliferation, we generated mixed BM 
chimeric mice by reconstituting lethally irradiated TLR4 deficient (Tlr4-/-) mice 
(CD45.1+/2+) with 1x106 WT (CD45.1+) and Tlr4-/- (CD45.2+) total BM cells in a 1 to 1 
ratio (WT;Tlr4-/- BM chimeric Tlr4-/- mice). Upon establishment of hematopoietic 
homeostasis after 2-3 months, mice were treated for two weeks with BrdU, followed 
by 4 time application of PBS or LPS, respectively (Figure 1D). Within the same PBS-
treated recipients WT and Tlr4-/- HSCs retained BrdU similarly. In contrast, 
proliferation was enhanced upon LPS treatment in both, WT and Tlr4-/- HSCs in the 
same animal, however, WT HSCs proliferated significantly more (Figure 1E and 1F). 
Thus, while some proliferation depends on hematopoietic cell secreted factors from 
WT hematopoiesis in these chimeric animals (the delta between proliferation of 
TLR4-/- HSCs upon PBS and LPS treatment), a significant, about equally sized part of 
proliferation is driven by direct TLR4 stimulation of HSCs (the delta between 
proliferation of WT and TLR4-/- HSCs upon LPS treatment). In order to further test the 
TLR4-mediated direct HSC activation, we employed CFSE (Carboxyfluorescein 
diacetate succinimidyl ester)-based high sensitive HSC divisional tracking1. Highly 
purified WT HSCs (LKS CD34-CD48-CD41-CD150+) or MPPs (LKS CD34+) were 
labeled with CFSE and transferred into non-irradiated steady state Tlr4-/- recipients. 
Mice were i.p. treated with PBS or LPS twice or trice starting at 2 days after the 
transfer and analyzed at day 6 to determine divisional history of donor-derived HSC 
or MPPs based on CFSE dilution (Figure 1G). Almost all of transferred HSCs were 
found quiescent in the non- or 1x divided fraction of PBS-treated animals 6 days after 
initial transfer. In contrast, LPS injections significantly decreased the relative 
percentage of 0-1x divided cells and consecutively increased the percentage of 2-5x 
divided cells, indicating direct, LPS-induced HSC proliferation (Figure 1H and 1I). A 
similar effect occurred also in MPPs although less pronounced. 
Collectively, we conclude that highly purified HSCs can be activated from 
dormancy to cell cycle via direct TLR4 stimulation in vivo and that in settings of 
systemic LPS spread, HSC population divisional activation occurs with about equal 
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strength through direct TLR4-activation on HSCs and indirect, non-hematopoietic 
cell-mediated pathways. 
 
LPS challenge impairs competitive repopulating and self-renewing capacity of 
HSC through direct TLR4 activation 
Previous studies have shown that chronic exposure of HSC to LPS damages HSC 
function as defined by decreased competitive transplantation and hematopoietic 
reconstitution112,113,109. However, it remained unclear whether LPS-induced HSC 
dysfunction is mediated by TLR4 expression on non-hematopoietic or hematopoietic 
cells, or both. To dissect this, we employed Tlr4-/- and WT mixed BM chimeric mice 
(Figure 2A). Three months after transplantation, chimeric mice were i.p. injected with 
PBS or LPS (35 μg) every other day 8 times over two weeks, respectively. The 
relative chimerism of donor-type cells (ratio of Tlr4-/-- to WT-derived cells) in three 
major blood lineages (CD19+ B cells, CD3 + T cells and Mac-1+Gr-1+ granulocytes) in 
peripheral blood (PB) was tested monthly for up to 5 months after the last injection. 
Chimerism of Tlr4-/-- and WT-derived cells was equal in all the lineages before the 
injections, resulting in a ratio of 1, and remained unchanged over time upon PBS 
injections as expected (Figure 2B and 2C). In contrast, a significant increase in the 
relative chimerism of Tlr4-/- cells over WT cells was detected in LPS injected animals, 
indicating that WT cells were outcompeted by Tlr4-/- cells. Terminal BM analysis 
revealed that, similar as in mature blood cells, hematopoietic stem and progenitor cell 
populations (HSC (LKS CD34-), MPP (LKS CD34+), CMP/GMP (LK CD34+), and 
MEP (LK CD34-)) in BM were dominated by Tlr4-/- cells (Figure 2D), indicating that 
hematopoietic dominance of Tlr4-/- mature cells was due to higher proliferative activity 
of most upstream but not downstream cell populations. As both WT and Tlr4-/- 
hematopoiesis coexisted in the same mice and thus were exposed to the same 
environment, these data demonstrate that LPS activates TLR4 directly on WT cells 
and impairs their competitive repopulating ability, leading to dominance of Tlr4-/- 
hematopoiesis. 
To test if the LPS-induced competitive repopulating disadvantage of WT cells 
resulted from a functional defect in self-renewing HSC, we transplanted 1-2x106 total 
BM cells of primary recipients into lethally irradiated secondary recipients. Strikingly, 
we found that the same effect was sustained in PB and BM of secondary recipients 
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over 4 months, the longest time of follow-up (Figure 2E and 2F). Thus, the LPS-
induced deficiency indeed affected HSCs. 
To further evaluate if direct TLR4 activation on hematopoietic cells is sufficient 
for the observed findings with an alternative method, we generated WT;Tlr4-/- BM 
chimeric mice on a Tlr4-/- background, and subsequently challenged these with PBS 
or LPS. The competitive disadvantage of WT cells compared to Tlr4-/- cells upon in 
vivo LPS treatment was even more pronounced in the Tlr4-/- compared to WT 
recipients (Figure 2G and H), again documenting the consequence of direct TLR4 
ligation on HSPC and their subsequent relative competitive deficiency. 
As infection or LPS challenge is known to mobilize HSPC into the circulation, 
in part via up-regulation of endothelial cell-produced G-CSF78,107, the observed LPS-
TLR4-induced competitive HSC dysfunction might be due to differential mobilization 
and homing of WT versus Tlr4-/- HSC, resulting in the out-competition of WT HSCs in 
the BM. However, we were not able to detect differential mobilization of WT versus 
Tlr4-/- HSPCs in chimeric animals (data not shown). If a competitive re-homing 
disadvantage after LPS challenge would account for the observed out-competition, 
HSPC potential should be conserved in a non-competitive setting in WT cells. To test 
this, we injected PBS or LPS into WT mice, and isolated 3,000 LKS from BM 4 weeks 
after the last treatment when LPS-mobilized HSCs had migrated back to BM, as 
evidenced by a normal HSPC profile in BM and spleen (data not shown). The 
isolated LKS cells (CD45.2+) were then co-transplanted with an equal number of 
3,000 competitor LKS cells (CD45.1+) to lethally irradiated WT mice (CD45.1/2+) 
(Figure S2A). Subsequent monthly PB and terminal BM analysis showed that WT 
LKS isolated from LPS-pretreated mice harbored significantly reduced competitive 
repopulation capacity compared to WT LKS from PBS-pretreated mice (Figure S2B 
and S2C), demonstrating that LPS challenge damages HSC function, irrespective of 
possible migration effects in chimeric mice.  
Taken together, these data directly demonstrate that in vivo repetitive TLR4 
activation on HSCs impinges on their competitive self-renewing and repopulating 
ability. 
 
LPS-induced functional HSC impairment is dependent on TRIF- but not Myd88-
mediated signaling 
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In mature innate immune cells such as macrophages or dendritic cells, TLR4 ligation 
activates two distinct signaling cascades, mediated by two adaptor proteins carrying 
TIR (Toll-Interleukin receptor) domains, MYD88 (myeloid differentiation primary 
response 88) and TRIF (also called TICAM-1, toll-like receptor adaptor molecule 1), 
that both lead amongst others to NFκB activation at an early and later phase, 
respectively114. However, it is not known which TLR4-downstream signaling 
cascades are active in HSCs. We therefore investigated if the two adaptor molecules 
MYD88 and TRIF are involved in the LPS-induced HSC dysfunction. As acute 
inflammation was shown to enhance Sca-1 expression on HSPC26, we tested if LPS 
challenge up-regulated Sca-1 expression, and if genetic deletion of either Myd88 or 
Trif might abrogate it. A single LPS injection (35 μg) into WT mice induced strong 
Sca-1 up-regulation in BM Lin- cells 16 hours post treatment, resulting in an increase 
in the absolute number of phenotypic LKS and HSC (LKS CD34-CD150+) (Figure 3A-
C). Surprisingly, Trif-/- mice, but not Myd88-/- mice, failed to increase Sca-1 expression 
on HSPCs, similar as observed in Tlr4-/- mice, thus indicating downstream TLR4 
signaling via TRIF but not MyD88 in HSPCs. Consistent with this phenotypic 
observation, WT mice, reconstituted with WT and Myd88-/- or Trif-/- cells resulting in 
hematopoietic chimeras, and subsequently treated with PBS or LPS (Figure 3D), 
showed a competitive repopulation advantage for Trif-/- but not Myd88-/- cells over WT 
cells (Figure 3E and 3F). These data demonstrate that the functional defect of HSCs 
following direct TLR4 activation is mediated via TRIF- but not MYD88-signaling 
pathways. 
 
Pharmacological inhibition of ROS and p38 activation prevents LPS-TLR4-
TRIF-induced HSC dysfunction 
To further characterize the downstream signaling cascade responsible for LPS-TLR4-
TRIF mediated HSC alteration, we tested selective small inhibitors of TLR4 
downstream signaling (Figure S3A). WT mice were treated with the respective 
inhibitor 24 and 5 hours before LPS injection (Figure S3B). BM analysis 16 hours 
post LPS injection showed that the phenotypic expansion of HSCs (LKS CD34-
CD150+) upon LPS treatment was significantly suppressed by pretreatment with 
inhibitors against reactive oxygen species (ROS), NAC (N-acetyl-L-cysteine), and 
against p38 MAPK (mitogen-activated protein kinase), SB203580 or SB202190 
(thereafter called SB)115, but not by those against ERK1/2 (MAPK 1 and 2) and 
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against NFκB (nuclear factor of kappa light polypeptide gene enhancer in B cells), 
NaS (sodium salicylate)116 or NBD peptide (a cell permeable NEMO-binding domain 
peptide)117 (Figure S3C and S3D). The most significant suppression of phenotypic 
HSC expansion was achieved when mice were treated with both ROS and p38 
inhibitors (NAC/SB). Consistent with these findings and observations made in innate 
immune cells118, flow-cytometric analysis confirmed intracellular ROS production and 
p38 activation as early as 2 hours after in vivo LPS application in HSCs (LKS CD34-) 
and MPPs (LKS CD34+) but not in CMP/GMP (LK CD34+) (Figure S3E). 
We addressed if ROS/p38 inhibitors can block LPS-induced proliferation of 
HSCs. WT;Tlr4-/- BM chimeric Tlr4-/- mice were treated with BrdU for 2 weeks and 
subsequently with NAC and SB at 24 and 5 hours prior to PBS or LPS injection for 4 
cycles (Figure 4A). BM analysis one week after the final injection revealed that 
combined inhibitor treatment abolished the LPS-induced increase in proliferation of 
both, WT and Tlr4-/- HSC (Figure 4B).  
We next addressed the question if inhibition of the ROS-p38 mediated 
signaling pathway can prevent the LPS-induced competitive disadvantage of HSCs. 
WT;Tlr4-/- BM hematopoietic chimeric mice were treated with 8 cycles of sequential 
inhibitors and LPS applications, and the relative contribution of Tlr4-/- over WT cells to 
hematopoietic chimerism in PB and BM was determined (Figure 4C). Strikingly, the 
combined NAC/SB treatment prior to LPS completely abolished the competitive 
disadvantage of WT hematopoiesis in PB (Figure 4D). The same effect was observed 
in HSCs, LKS and LK in BM upon termination of the experiment (Figure 4E). 
Together these data demonstrate that activation of ROS and p38 through 
TLR4-ligation is a key step to cause HSC dysfunction and that this dysfunction can 
be prevented by respective pharmacological blockade.  
 
Emergency granulopoiesis depends on TLR4-MYD88 but not TRIF-ROS-p38 
signaling 
We recently demonstrated that systemic LPS- or bacterial infection-driven 
granulopoiesis, i.e. emergency granulopoiesis, is mediated by TLR4-MYD88 
signaling in endothelial cells and subsequent G-CSF release78,108. Given our findings 
on TLR4-TRIF but not TLR4-MyD88 mediated signaling in HSCs, we determined if 
TRIF-deficiency would affect LPS-induced emergency granulopoiesis. As expected 
and previously shown, in vivo LPS challenge of Tlr4-/- and Myd88-/- mice resulted in 
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absence of the enhanced granulopoiesis, whereas Trif-/- mice showed an intact 
emergency granulopoietic response (Figure S4A-C). Moreover, none of the inhibitors 
tested had a suppressive effect on LPS-induced emergency granulopoiesis (Figure 
S4D and S4E).  
Together these data demonstrate that immediate emergency granulopoiesis 
and HSC activation via TLR4 are differentially regulated by Myd88- and TRIF-
dependent signals, respectively. 
 
TLR4 stimulation induces genotoxic stress in HSCs via ROS-p38 signaling 
Increased levels of ROS are associated with cell cycle induction64 and attenuated 
HSC function during serial transplantation115. Also, ROS can cause DNA breaks and 
chromosomal aberrations in BM cells of a Fanconi anemia mouse model119. We thus 
tested if TLR4-mediated ROS production leads to genotoxic stress in HSCs. Mice 
were treated with PBS or LPS for 8 times, and HSCs (LKS CD34-CD150+ or LKS 
CD34-CD48-CD41-CD150+) and myeloid progenitors (LK or LK CD34-CD48-CD41-) in 
BM were analyzed at different time-points after the last injection (Figure 5A). Cells 
were stained with antibodies against phosphorylated H2AX (γH2AX), a surrogate 
marker for DNA damage response120,121, and γH2AX+ foci formation was visualized 
and quantified. The proportion of cells with more than three γH2AX+ foci was 
significantly increased in both HSCs and their progeny upon LPS treatment, and was 
comparable to that observed in mice that were gamma-irradiated (2Gy) two hours 
before analysis (Figure 5B and 5C). Surprisingly, LPS-induced γH2AX+ foci were 
maintained for longer than 14 days in vivo, indicating sustained genotoxic stress 
upon LPS challenge. 
As it was recently shown that γH2AX+ foci formation results from replication 
defects in cycling HSCs rather than from DNA double-strand breaks122, we analyzed 
if γH2AX+ foci correlate with cell cycle induction in HSCs. Snap-shot cell cycle 
analysis showed that a higher fraction of HSCs (LKS CD34-CD150+) were found in 
G1 at day 3 post LPS injection, but regained normal cell cycle distribution at day 14 
(Figure 5D and 5E), while there was no significant difference in actively cycling 
myeloid progenitors (LK), consistent with BrdU labeling and dilution experiments in 
Figure 1B. The apoptotic rate was similar in PBS- and LPS-stimulated HSCs at any 
time point analyzed (data not shown). We then addressed if ROS/p38 inhibitors can 
block γH2AX+ foci formation. When WT mice were treated with NAC and SB prior to 
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LPS injections for 8 cycles (Figure 5F), the percentage of HSCs and their progeny 
carrying γH2AX+ foci at day 3 post treatment was significantly suppressed (Figure 
5G), indicating that the foci formation is mediated by the ROS-p38 pathway.  
Taken together, the increase of ROS levels and p38 activation upon LPS 
challenge leads to proliferation and causes sustained genotoxic stress in HSCs that 
can be blocked by ROS-p38 inactivation. 
 
Discussion 
In this study, we provide for the first time definitive in vivo evidence that i) quiescent 
HSCs in the BM sense systemically spread LPS directly via HSC expressed TLR4 
and subsequently increase cycling, that ii) TLR4-stimulation on HSCs impairs their 
competitive repopulation ability and causes genotoxic stress via TRIF-mediated, but 
not MyD88-mediated, ROS-p38 signaling, and that iii) pharmacologic inhibition of 
TLR4-TRIF-ROS-p38 signaling prevents LPS-induced HSC dysfunction. 
 Although not directly addressed in our study, one might speculate that LPS 
(and possibly other PAMP) sensing by HSCs and subsequent proliferation might 
enhance hematopoietic cell production in situations of need, and thus has been 
advantageous and selected in evolution. However, by employing BM chimeric mice 
with one half of hematopoietic cells expressing TLR4 and the other half not 
expressing it, our study clearly demonstrates that Tlr4-/- HSCs are also induced to 
divide upon LPS injection, a process that must be driven by secondary, extrinsic 
signals such as pro-inflammatory cytokines secreted from TLR4-expressing non-
hematopoietic (in the case of a TLR4 WT environment) or hematopoietic cells (in the 
case of a hematopoietic WT;Tlr4-/- chimera in a TLR4-/- non-hematopoietic 
environment). One potential cytokine involved in this process could be IL-6, which 
has been shown to be produced by HSPCs upon TLR4 activation63 and non-
hematopoietic BM cells via IFN-γ triggering upon viral infections83. As the relative 
contribution to HSC cycling by direct, HSC expressed TLR4-ligation and indirect, 
non-HSC expressed TLR4 ligation was of about equal strength in the experimental 
settings in our study, it will be challenging to dissect in which in vivo infectious 
disease situation the direct TLR4-mediated response will provide a distinct advantage 
to hematopoietic regulation and subsequent host defense and survival. 
The observed negative consequence of direct LPS-TLR4-mediated HSC 
activation is a compromised competitive capacity of HSCs, defined by both 
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decreased hematopoietic output in competition with control-stimulated HSCs upon 
transplantation, as well as in a relative loss of TLR4-stimulated HSC numbers 
compared to TLR4-signaling deficient HSC controls. These findings are in line with 
the observation that LPS application over one month resulted in reduced lymphoid 
repopulation from HSCs in competitive conditions113. 
By dissecting TLR4 downstream signaling in HSCs, we found that HSC signal 
via the TLR4-associated TIR adaptor protein TRIF, but not MYD88. TLR4-TRIF 
triggers a downstream signaling cascade via ROS-p38, which causes cell cycle 
progression in HSC and leads to a genotoxic stress response that is marked by the 
phosphorylation of H2AX, previously reported as p38 target123. We here demonstrate 
that both genetic and pharmacological inactivation of this pathway can block HSC 
proliferation and dysfunction in response to LPS. Indeed, it has been reported that 
activation of the ROS-p38 axis upon serial transplantation results in decreased 
quiescence and impaired repopulating ability of HSCs115. In addition, we here 
demonstrate that pretreatment of HSCs with ROS-p38 inhibitors prior to LPS 
challenge maintained HSC function. This is in line with the findings that inhibition of 
ROS-p38 sustains HSC function in vivo 109,124,125 and also supports ex vivo expansion 
of both mouse and human HSCs126,127. On the contrary, dysregulation of ROS-p38 
signaling was proposed to be a hallmark of stem cell ageing128. Moreover, it was 
shown that scavenging ROS restored the quiescence and regenerative potential of 
different somatic stem cells115,124,129, and blockage of ageing-associated p38 
activation ameliorated the functional decline in aged muscle stem cells130. How ROS-
p38 activation causes HSC proliferation and dysfunction, genotoxic stress and the 
associated H2AX+ foci formation, as well as possible subsequent genetic alterations 
is still controversial, with several studies demonstrating varying results122,131,132. Thus, 
we do not know from the data presented here if the observed enhanced cycling and 
genotoxic stress results in functional HSC attrition64 or if, at least in some cases, also 
results in genetic lesions in HSCs. However, it is of interest that population-based 
epidemiological studies showed a significant positive correlation of infectious and 
inflammatory states and the incidence of HSPC diseases, such as acute myeloid 
leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms65. 
Furthermore, a recent study also has shown that TLR4-TRAF6 signaling enhanced 
by deficiency of TIFAB (TRAF-interacting protein with forkhead-associated domain 
B), a haplo-insufficient gene in del(5q) myelodysplastic syndrome, causes inefficient 
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hematopoiesis125. Thus, if direct stimulation of PAMPs on HSPCs can indeed 
enhance acquisition of genetic events that lead to hematopoietic deficiency, clonal 
dominance, and finally malignant hematopoietic disease, need to be determined in 
future studies. 
TLR4 stimulation induces progenitor cell division and differentiation to myeloid 
cells via MYD8859,60 and TLR4 stimulation also induces MYD88 dependent G-CSF 
secretion from endothelial cells, leading to subsequent emergency granulopoiesis78. 
In contrast, we show here that TLR4 stimulation in bona fide HSCs leads to TRIF-, 
but not the MYD88-dependant signaling, revealing differential use of TLR4-
downstream pathways in different cells of the hematopoietic hierarchy. We thus 
tested if ablation or inhibiting TRIF-mediated signaling would negatively affect 
emergency granulopoiesis. Interestingly, this was not the case. Therefore, it might be 
feasible to prevent HSC from LPS-induced functional impairment by pharmacologic 
TRIF-dependent signaling pathway inhibition, while at the same time preserving 
indirect HSC cycling induction as well as emergency granulopoiesis in order to 
augment innate immunity against systemically spread, life-threatening gram-negative 
infection. 
In summary, our findings highlight a direct pathogen sensing mechanism in 
self-renewing HSCs that leads to HSC proliferation but decreases their regenerative 
capacity. Intervention into the TRIF-ROS-p38 signaling axis has the potential to 
prevent HSC dysfunction, likely without inhibition of short-term protective responses 
against pathogen insults. If inhibition of this pathway as means of preemptive 
medicine will also allow to retard ageing-associated HSC defects and ageing-
associated malignant transformation, will need to be determined in future studies.  
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Experimental Procedures 
 
Mice 
Tlr4-/-, Trif-/-, and Myd88-/- mice (CD45.2+) were kindly provided by Dr. Shizuo Akira 
(Osaka University). C57BL/6 (CD45.2+) and B6.SJL (CD45.1+) mice were obtained 
from Jackson Laboratories. 
 
Generation of BM chimeric mice, LPS challenge and serial transplantation 
WT or Tlr4-/- mice (CD45.1/2+) were lethally irradiated with 9.5Gy and i.v. 
transplanted with equal numbers (1:1 ratio) of 1x106 total BM or 3,000 Lin-c-Kit+Sca-
1+ cells from WT and Tlr4-/-, Trif-/-, or Myd88-/- animals. Two to three months after 
reconstitution, BM chimeric mice were i.p. injected with 35-50 μg LPS corresponding 
to 35-50 EU. In serial transplantation experiments, 1-2x106 total BM cells from 
chimeric mice were serially transplanted into lethally irradiated WT (CD45.1/2+) mice. 
 
FACS analysis and sorting 
Donor chimerism in peripheral blood, BM and spleen were analyzed on a FACS 
Canto II. For snap-shot cell cycle analysis, total BM cells were stained with antibodies 
against cell surface antigens, Ki67 (B56) antibody and Hoechst33342 for DNA. For 
TLR4 expression, total BM cells were incubated with an antibody against TLR4/MD-2 
complex together with early hematopoietic cell markers. LKS cells, MPPs or HSCs 
were sorted on a FACS Aria III (BD Biosciences).  
 
Quantitative RT-PCR 
HSC and HPC from BM, or mature cell populations from BM and spleen were sorted 
directly into lysis buffer and subjected to RNA isolation, cDNA synthesis and Real 
Time PCR with primers specific to the following genes: Tlr4, Trif, Myd88, Mpl and 
Actb. Relative mRNA expression of each gene was normalized against relative 
expression of beta-actin. 
 
Kaplan-Meier survival following 5FU administration 
WT mice were i.p. pretreated with PBS or 35 μg LPS, 1 and 3 days or 5 and 7 days 
before two i.p. injections of 5-FU (150 mg/kg) in a weekly interval. The survival of 
animals was followed over one month. 
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In vivo inhibitor treatment 
BM chimeric mice were i.p. injected with 100 mg/kg NAC and 15 mg/kg SB203580 24 
and 5 hours before PBS or LPS treatment, respectively. 
 
BrdU labeling and retention 
WT or mixed BM chimeric mice were i.p. injected with 9 mg/kg BrdU and 
subsequently put on drinking water containing 800 μg/ml BrdU and 5% sucrose for 
two weeks followed by normal water for another two weeks until analysis. One week 
after final PBS or LPS injections, BM cells were harvested and stained with 
antibodies against cell surface antigens and BrdU. 
 
CFSE labeling and chasing 
HSCs (3,000-7,835 LKS CD34-CD48-CD41-CD150+ cells) or MPPs (113,250 LKS 
CD34+ cells) isolated from WT mice (CD45.2+) were labeled with CFSE as previously 
described (Takizawa JEM 2011) and i.v. transferred into Tlr4-/- mice (CD45.1+). Two 
or three days later, mice were treated with PBS or 100 μg LPS for 2 or 3 times and 
were analyzed on day 6 to determine CFSE dilution in HSCs and MPPs. 
 
Immunocytochemistry 
HSCs (LKS CD34-CD48-CD41-CD150+) and LK CD34-CD48-CD41- cells were sorted, 
fixed with 4% PFA for 10 min and permeabilized with 0.5% Triton X-100. γH2AX foci 
and nuclei were visualized with anti-phospho-histone H2AX antibody and DAPI, 
respectively, and images were taken on a Leica SP5 with a 63x objective lens 
(Leica). 
 
Statistical analysis 
All data are shown as the mean ± s.e.m., unless indicated otherwise. Kaplan-Meier 
survival was analyzed by Log-rank test on GraphPad Prism 5 (GraphPad software, 
Inc). All statistical comparisons were evaluated with Student’s t-Test. ns, not 
significant; *p<0.05; **p<0.01; ***p<0.001 (two-tailed t-test). 
 
Supplemental Information 
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Supplemental Information for this article includes four figures and Supplemental 
Experimental Procedures and can be found with this article online. 
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Figure legends 
 
 
 
Figure 1. LPS increases proliferation of HSCs via direct TLR4 activation. (A) 
Experimental scheme of the BrdU label retention assay for results depicted in (B): 
WT mice were treated with 9 mg/kg BrdU i.p. once and fed with 800 μg/mL BrdU 
containing water for 2 weeks. Mice were then treated with PBS or LPS injections 2 or 
4 times and BrdU label retention was determined in BM populations 1 week after the 
last injection. (B) Representative histogram of BrdU label in HSC (LKSCD34-CD150+) 
from animals injected with 4xPBS, 2xLPS, and 4xLPS. Right panel depicts 
percentage of BrdU+ HSCs (LKSCD34-CD150+), MPPs (LKSCD34+), LKS and LK 
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cells (4xPBS: n=3; 2xLPS: n=3; 4xLPS: n=4). Each dot represents data from 
individual animals. (C) Survival of mice treated as indicated with PBS (Group A: day -
3 and -1; n=6) or LPS (35 μg) injections (Group B: day -3 and -1; n=7; Group C: day -
7 and -5; n=5) followed by i.p. application of 150 mg/kg 5-FU at day 0 and 7. (D) 
Experimental scheme of BrdU label retention assay for results depicted in (E) and 
(F): Tlr4-/- mice were reconstituted with WT and Tlr4-/- BM in a 1:1 ratio (mixed 
WT;Tlr4-/- BM hematopoietic chimeric Tlr4-/- mice). Eight weeks after reconstitution, 
the mixed BM chimeric mice were given BrdU containing water for 2 weeks and 
injected with PBS or LPS (50 μg) 4 times followed by BM analysis 1 week post the 
last injection. (E) Representative histogram of BrdU label in WT and Tlr4-/- HSC 
(LKSCD34-CD150+) from PBS- or LPS-treated mixed WT;Tlr4-/- BM hematopoietic 
chimeric Tlr4-/- mice. (F) Percentage of BrdU+ HSCs derived from WT or Tlr4-/- donors 
in mixed BM chimeric Tlr4-/- mice upon PBS or LPS injections (PBS, n=7; LPS, n=8). 
(G) Experimental scheme of CFSE based cell divisional tracking. Tlr4-/- mice were 
transplanted with CFSE-labeled WT HSCs (LKS CD34-CD48-CD150+) or MPPs (LKS 
CD34+), and i.p. injected 2 or 3 times with PBS or 100 μg LPS followed by BM 
analysis at day 6. (H) Representative FACS plots of CFSE dilution versus the 
respective marker indicated, in donor-derived HSC (LKS CD34-) or MPP (LKS 
CD34+) from PBS (blue)- or LPS (red)-treated mice that had been previously 
transplanted with HSC (left) or MPP (right). (I) Percentage of 0-1x divided cells and 
proliferating (2-5x divided) cells within donor-derived HSC (PBS, n=8; LPS, n=9) and 
MPP (PBS, n=4; LPS, n=4). Data are pooled from 2-3 independent experiments. ns, 
not significant; *p<0.05; **p<0.01, ***p<0.001 (two-tailed t-test). 
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Figure 2. TLR4 activation impairs competitive self-renewing and repopulating 
capacity of HSC. (A) Experimental scheme of LPS challenge in mixed WT;Tlr4-/- BM 
chimeric animals for results depicted in (B-H): lethally irradiated WT or Tlr4-/- mice 
were reconstituted with WT (CD45.1+) and Tlr4-/- (CD45.2+) cells. Twelve weeks after 
reconstitution, mice were i.p. treated with PBS or LPS (35 μg) for 8 times every other 
day, followed by monthly PB analysis of hematopoietic chimerism, starting at 1 month 
after the last injection. Twenty to thirty-six weeks post transplantation, total BM cells 
from primary recipients were serially transplanted into lethally irradiated secondary 
WT recipients (CD45.1/2+). Secondary recipients were assessed monthly for PB 
chimerism and BM was analyzed at termination of the experiment. (B) 
Representative flow-cytometric profiles of WT (CD45.1+) and Tlr4-/- (CD45.2+)-derived 
granulocytes (Mac-1+Gr-1+) in WT;Tlr4-/- BM chimeric WT mice before (left) and 20 
weeks after (right) PBS- (top) or LPS- (bottom) treatment. (C) Ratio of Tlr4-/-- to WT-
derived CD45+ cells, CD19+ B cells, CD3+ T cells and Mac-1+Gr-1+ granulocytes in 
PB of primary WT recipients (PBS: n=6-14; LPS: n=6-13). (D) Ratio of Tlr4-/-- to WT-
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derived HSCs (LKSCD34-), MPPs (LKSCD34+), CMPs+GMPs (LKCD34+) and MEPs 
(LKCD34+) in BM of primary WT recipients 18-36 weeks post treatment (PBS: n=11; 
LPS: n=15). (E) Ratio of Tlr4-/-- to WT-derived CD45+ cells, CD19+ B cells, CD3+ T 
cells and Mac-1+Gr-1+ granulocytes in PB of secondary WT recipients (PBS: n=8; 
LPS: n=9). (F) Ratio of Tlr4-/-- to WT-derived HSCs, MPPs, CMPs+GMPs and MEPs 
in BM of secondary WT recipients 33 weeks post treatment (PBS: n=5; LPS: n=5). 
(G) Ratio of Tlr4-/-- to WT-derived CD45+ cells, CD19+ B cells, CD3+ T cells and Mac-
1+Gr-1+ granulocytes in PB of primary Tlr4-/- recipients (PBS: n=8-12; LPS: n=10-13). 
(H) Ratio of Tlr4-/-- to WT-derived HSCs (LKSCD34-), MPPs (LKSCD34+), 
CMPs+GMPs (LKCD34+) and MEPs (LKCD34+) in BM of primary Tlr4-/- recipients 20 
weeks post treatment (PBS: n=5; LPS: n=8). Data are pooled from 2-5 independent 
experiments. ns, not significant; *p<0.05; **p<0.01; ***p<0.001 (two-tailed t-test). 
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Figure 3. LPS-induced expansion and dysfunction of HSC is mediated by TLR4-
TRIF signaling. (A) Experimental scheme of acute LPS challenge for results 
depicted in (B) and (C): WT, Tlr4-/-, Myd88-/-, and Trif-/- mice were injected with PBS 
or LPS (35 μg) once, and BM was analyzed 16 hours post injection for phenotypic 
HSC. (B) Representative flow-cytometric profiles of LKS in BM of WT, Tlr4-/-, Myd88-/-
, and Trif-/- mice treated with PBS or LPS (upper and lower panel, respectively). (C) 
Number of LKS or phenotypic HSCs (LKSCD34-CD48-CD41-CD150+) in BM 
calculated from 3 independent experiments (PBS: n=3-7; LPS: n=3-6). (D) 
Experimental scheme of LPS challenge to BM chimeric mice for results depicted in 
(E) and (F): lethally irradiated WT (CD45.1/2+) mice were reconstituted with WT 
(CD45.1+) and Myd88-/- (CD45.2+) or WT and Trif-/- (CD45.2+) cells in a 1:1 ratio, and 
3 months later treated with PBS or LPS (35 μg) for 8 times over two weeks. (E) 
Monthly analysis of Trif-/-- or Myd88-/-- to WT-derived granulocyte (Mac-1+Gr-1+) ratio 
in PB of mixed BM chimeric mice after the last PBS or LPS injection (Trif-/--PBS: n=4-
11; Trif-/--LPS: n=8-13; Myd88-/--PBS: n=9-10; Myd88-/--LPS: n=10). Data are pooled 
from 2-5 independent experiments. ns, not significant; *p<0.05; **p<0.01; ***p<0.001 
(two-tailed t-test). 
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Figure 4. Pharmacological inhibition of ROS-p38 signaling prevents HSC 
proliferation and exhaustion upon LPS challenge. (A) Experimental scheme of 
BrdU label retention with or without NAC and SB for results depicted in (H): eight 
weeks after reconstitution of Tlr4-/- mice with WT or Tlr4-/- cells in a 1:1 ratio, mice 
were given BrdU containing water for 2 weeks and treated with 4 cycles of NAC (-
24h) and SB (-5h) (NAC/SB) prior to each four PBS or LPS (50 μg) injections, 
followed by BM analysis 1 week after the last injection. (B) Percentage of BrdU+ 
HSCs (LKSCD34-CD150+) derived from WT or Tlr4-/- donors upon PBS or LPS 
injections with or without NAC and SB (PBS+DMSO: n=9; PBS+NAC/SB: n=11; 
LPS+DMSO: n=9; LPS+NAC/SB: n=11). (C) Experimental scheme of PBS or LPS 
challenge to mixed WT;Tlr4-/- BM chimeric mice, with or without NAC and SB for 
results depicted in (D) and (E): Twelve weeks after transplantation of WT or Tlr4-/- 
mice with WT and Tlr4-/- cells in a 1:1 ratio, mice were treated with 8 cycles of NAC (-
24h) and SB (-5h) prior to PBS or LPS (35 μg) injections followed by monthly PB 
chimerism analysis and terminal BM analysis. (D) Ratio of Tlr4-/-- to WT-derived 
granulocytes (Mac-1+Gr-1+) in PB of the mixed BM chimeras are shown 
(PBS+DMSO: n=4; PBS+NAC/SB: n=4; LPS+DMSO: n=3; LPS+NAC/SB: n=4). The 
ratio from PBS+DMSO, PBS+NAC/SB, and LPS+NAC/SB treated mice was 
statistically compared with that from LPS+DMSO treated mice. (E) Ratio of Tlr4-/-- to 
WT-derived HSCs (LKSCD34-), MPPs (LKSCD34+), CMPs+GMPs (LKCD34+) and 
MEPs (LKCD34+) in BM of mixed BM chimeric mice at terminal analysis 22 weeks 
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post treatment (PBS+DMSO: n=4; PBS+NAC/SB: n=4; LPS+DMSO: n=3; 
LPS+NAC/SB: n=4). Data are pooled from 2-5 independent experiments. ns, not 
significant; *p<0.05; **p<0.01 (two-tailed t-test). 
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Figure 5. LPS induces DNA stress responses in HSCs via ROS-p38 activation. 
(A) Experimental scheme of sustained LPS challenge for results depicted in (B-E): 
WT mice were treated with PBS or LPS (50 μg) 8 or 12 times every other day, and 
BM were processed for cell cycle analysis or sorting at different time points (3, 14, 
≥35d) after the last injection. (B) Representative confocal microscopic images of co-
localization of γH2AX+ (red) foci in nuclei (blue) of HSCs (LKSCD34-CD48-CD41-
CD150+) and LK CD34-CD48-CD41- cells at day 3 after PBS or LPS treatment or at 2 
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hours after 2Gy irradiation. White bars indicate 5 μm. (C) Time course kinetics of 
H2AX+ foci formation in HSCs and LK CD34-CD48-CD41- cells from PBS- (blue) or 
LPS- (red) treated mice, in comparison with those from animals 2 hours after 2Gy 
irradiation (green). The percentage of cells with >3 γH2AX+ foci is shown. The 
number of PBS or LPS injections is indicated above each bar. (D) Representative 
flow-cytometric cell cycle analysis of HSCs (LKS CD34-CD150+) and LK cells at 3 
and 14 days after the last injection. (E) Percentage of each cell cycle phase (G0, G1 
and S/G2/M) of HSCs and LK cells (PBS: n=4-5; LPS: n=4-5 at each time point). (F) 
Experimental scheme of DNA damage response upon LPS application in the 
presence or absence of NAC and SB for results depicted in (G): WT mice were 
treated with 8 cycles of NAC (-24h) and SB (-5h) in prior to LPS injections. (G) The 
percentage of cells with >3 γH2AX+ foci in HSCs and LK CD34-CD48-CD41- cells 3 
days after the last LPS injection with or without NSC/SB. Data are pooled from 2-4 
independent experiments. n.d., not determined; ns, not significant; *p<0.05; **p<0.01; 
***p<0.001 (two-tailed t-test). 
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Supplementary figure 1. HSC and progenitors express TLR4/MD-2 complex. (A) 
Representative flow-cytometric profiles of HSCs and progenitors in BM of WT mice. 
Lin- BM cells were pre-gated and developed by c-Kit and Sca-1, and subsequently 
CD150 and CD34, or CD16/32 and CD34, to define the following populations: HSCs 
(LKSCD34-CD150+), MPPs (LKSCD34+), CMPs (LKCD16/32lowCD34+), GMPs 
(LKCD16/32hiCD34+) and MEPs (LKCD16/32lowCD34-). (B) Representative histogram 
of TLR4/MD-2 expression in HSCs, MPPs, CMPs, GMPs and MEPs (red: anti-
TLR4/MD2 antibody; gray: isotype-matched antibody). (C) Quantitative PCR analysis 
on mRNA expression of the indicated genes in FACS-sorted BM HSCs (LKS 
Flt3−CD34−CD48−CD150+), MPPs (LKS Flt3+CD34+), CMPs, MEPs 
(LKCD16/32lowCD34-), GMPs (LKCD16/32hiCD34+), dendritic cells (CD11c+MHCII+) 
from spleen and granulocytes (Mac1+Gr1+) from BM. Relative expression of the 
indicated genes to the expression of Actb is shown in respective cell populations 
(mean ± SEM). Data are pooled from 2-4 independent experiments. 
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Supplementary figure 2. Systemic LPS application limits competitive 
repopulating ability of HSCs, irrespective of LPS-induced HSC mobilization. (A) 
Experimental scheme of LPS treatment and transplantation for results depicted in (B) 
and (C): WT or Tlr4-/- mice were i.p. injected with PBS or LPS (35μg) 8 times every 
other day. Four weeks after the last injection, 3,000 LKS (CD45.2+) were isolated, 
and competitively transplanted with 3,000 non-stimulated competitor LKS (CD45.1+) 
into lethally irradiated WT mice (CD45.1/2+) followed by monthly PB chimerism 
analysis (B) and terminal BM analysis (C). (B) Percentage of donor derived CD45+ 
cells, CD19+ B cells, CD3+ T cells and Mac-1+Gr-1+ granulocytes in PB of recipients 
(PBS-WT: n=12; LPS-WT: n=14; LPS-WT: n=9). (C) Percentage of donor derived 
HSCs (LKSCD34-), MPPs (LKSCD34+), CMPs/GMPs (LKCD34+) and MEPs 
(LKCD34+) in BM of recipients at terminal analysis 22 weeks after reconstitution 
(PBS-WT: n=6; LPS-WT: n=7). Data are pooled from two independent experiments. 
ns, not significant; *p<0.05; **p<0.01; ***p<0.001 (two-tailed t-test). 
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Supplementary figure 3. Pharmacological inhibition of ROS-p38 signaling 
blocks expansion of phenotypic HSCs upon LPS challenge. (A) Schematic TLR4 
signaling cascades, leading to MAPKs and NFκB activation that are blocked by the 
respective indicated inhibitors. (B) Experimental scheme of single LPS challenge with 
or without inhibitors for results depicted in (C-E): WT mice were pretreated with 
vehicle or indicated inhibitors, 24 and 5 hours prior to single PBS or LPS (35 μg) 
injection. BM was analyzed 16 hours post PBS or LPS injections. (C) Representative 
flow-cytometric profiles of c-Kit and Sca-1 expression in Lin- BM cells are shown. (D) 
Number of HSCs (LKSCD34-CD48-CD41-CD150+) were calculated (PBS, n=3-6; 
LPS, n=5-9). Data from LPS applications with inhibitor were statistically compared to 
those from LPS with DMSO: *p<0.05; **p<0.01 (two-tailed t-test); Data from LPS 
application with or without inhibitor were statistically compared with those from their 
corresponding PBS control: *p<0.05; **p<0.001 (two-tailed t-test). (E) Representative 
histogram of p38 and ROS activation in HSCs (LKSCD34-), MPPs (LKSCD34+) and 
CMPs+GMPs (LKCD34+) upon LPS challenge: cells were isolated from BM at 0, 2 
and 16 hours post single PBS or LPS (35 μg) injection, and tested for p38 and ROS 
activation.  
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Supplementary figure 4. Emergency granulopoiesis is dependent on MYD88 
but not TRIF-ROS-p38 mediated pathways. (A) Experimental scheme of the acute 
LPS challenge of mice deficient for TLR4 signal-related molecules for results 
depicted in (B) and (C): WT, Tlr4-/-, Myd88-/-, and Trif-/- mice were injected with PBS 
or LPS (35 μg), and analyzed for BM granulopoiesis 16 hours post injection. (B) 
Representative flow-cytometric profiles of CD11b and Gr-1 expression in BM from 
WT, Tlr4-/-, Myd88-/-, and Trif-/- mice treated with PBS (upper) or LPS (lower) panel. 
(C) Ratio of CD11b+Gr-1low to CD11b+Gr-1hi cells in BM (PBS: n=3-5; LPS: n=3-5) (D) 
Experimental scheme of acute LPS challenge with or without inhibitors for results 
depicted in (E): WT mice were pretreated with vehicle or the respective indicated 
inhibitors, 24 and 5 hours prior to single PBS or LPS (35 μg) injection. (E) Ratio of 
CD11b+Gr-1low to CD11b+Gr-1hi cells in BM (PBS: n=3-5; LPS: n=3-5 for each 
inhibitor) Data are pooled from 3 independent experiments. ns, not significant; 
***p<0.001 (two-tailed t-test). 
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Supplemental Extended Experimental Procedures 
 
Mice 
CD45.1/2+ mice were generated by intercrossing C57BL/6 (CD45.2+) with B6.SJL 
(CD45.1+). Tlr4-/- mice were backcrossed on C57BL/6 (CD45.2+) or B6.SJL (CD45.1+) 
for more than six generations, and CD45.1/2+ Tlr4-/- mice were generated by 
interbreeding of both mice. All mice were maintained at the Institute for Research in 
Biomedicine and University Hospital Zurich animal facilities according to the 
guidelines of the Swiss Federal Veterinary Office. Experiments were approved by the 
Dipartimento della Sanità e Socialità, Ticino, Switzerland, and by the Veterinäramt of 
Kanton Zurich, Zurich, Switzerland. 
 
 
Generation of BM chimeric mice, LPS challenge and serial transplantation 
Six to twelve week old WT or Tlr4-/- mice (CD45.1/2+) were lethally irradiated with 
9.5Gy (split dose within a 2-4 h interval) and i.v. transplanted with equal numbers (1:1 
ratio) of 1x106 total BM or 3,000 Lin-c-Kit+Sca-1+ cells from WT and Tlr4-/-, Trif-/-, or 
Myd88-/- animals. Two to three months after reconstitution, the BM chimeric mice 
were i.p. injected with 35-50 μg LPS corresponding to 35-50 EU (Escherichia coli 
0111:B4, LPS-EB Ultrapure, Invivogen) according to the indicated schemes. 
Peripheral blood was harvested from the BM chimeric mice and the relative donor 
chimerism was assessed in mature hematopoietic cells. At terminal work-up, BM 
from chimeric mice was harvested and analyzed.  
 
FACS analysis and sorting 
All antibodies used in this study were purchased from Life technologies 
(eBiosciences) or Biolegend unless specified otherwise. For analyzing donor 
chimerism in mature hematopoietic cell, cells from BM, spleen, or peripheral blood 
(PB) were stained with antibodies against CD45.1 (A20), CD45.2 (104), CD19 (1D3), 
CD3  (2C11), Gr-1 (RB6-8C5) and CD11b (M1/70). For early hematopoietic cell 
analysis, cells from BM or spleen were incubated with antibodies against lineage 
(Lin) markers (NK1.1 (PK136), CD11b, Ter119 (Ter119), Gr-1 (RB6-8C5), CD4 
(RM4-5), CD8α(53-6.7), CD3ε (2C11), B220 (RA3-6B2), IL-7Rα (A7R34), c-Kit (2B8), 
Sca-1 (D7), CD34 (RAM34), Flt3 (A2F10), CD150 (TC15-12F12.2), CD48 (HM48-1), 
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CD16/32 (2.4G2). For LKS or HSC (LKSCD34-CD48-CD150+) sorting, total BM cells 
were stained with biotinylated antibodies against lineage markers, and lineage 
positive cells were depleted with streptavidin conjugated magnetic beads (Militenyi 
Biotec GmbH). The lineage depleted cells were stained with antibodies against c-Kit 
and Sca-1, and LKS or HSC were sorted on a FACS Aria III (BD Biosciences). For 
TLR4 expression, total BM cells were incubated with biotinylated an antibody against 
TLR4/MD-2 complex (MTS510, Life technologies) or an isotype-matched control 
antibody, together with early hematopoietic cell markers (Lin, c-Kit, Sca-1, CD34, 
CD150, CD16/32) for more than 90 min, and binding was detected by streptavidin 
conjugated brilliant violet 421. The samples were analyzed on a FACS Canto II. 
 
Quantitative RT-PCR 
HSC and HPC from BM were enriched for Lin- cells with biotin-conjugated lineage 
markers as described above. Cells were then stained with the antibodies against 
CD16/32 (2.4G2), c-Kit (2B8), Sca-1 (D7), Flt3 (A2F10), CD34 (RAM34), CD150 
(TC15-12F12.2). For mature cell populations, BM and spleen cells were stained with 
Mac1 (M1/70) and Gr-1, and MHCII (M5/114.15.2), CD11c (N418), respectively, and 
were directly sorted into lysis buffer containing β-mercaptoethanol. The cell lysate 
was subjected to RNA isolation (Qiagen), cDNA synthesis (Applied Biosystems) and 
qPCR with SYBER green reagent (Applied Biosystems) and the following gene 
specific primers on a 7500 Fast Real Time PCR System (Applied Biosystems): Tlr4 
(5’-CCA ATG CAT GGA TCA GAA ACT C-3’ ; 5’-ATT TCA CAC CTG GAT AAA TCC 
AGC-3’), Trif (5’-TAC AGC CAG GTC TGT GCT-3’ ; 5’-AGA ATG AAG CCT GGA 
GCC-3’), Myd88 (5’-TCG ATG CCT TTA TCT GCT ACT G-3’ ; 5’-TCT GTT GGA 
CAC CTG GAG AC-3’), Mpl (5’-GAA GCT GTC TCG TCT CAG G-3’ ; 5’- TCC AAT 
TGT CAC TGC ATC TCC-3’) and Actb (5’-AGA TGA CCC AGA TCA TGT TTG AG-3’ 
; 5’- GTA CGA CCA GAG GCA TAC AG-3’). Relative mRNA expression of each gene 
was normalized against relative expression of beta-actin. 
 
In vivo inhibitor treatment 
For inhibitor treatment, BM chimeric mice were i.p. injected with 100 mg/kg NAC 
(Calbiochem, CA, USA) for ROS, 15 mg/kg SB203580 or SB 202190 (Calbiochem) 
for p38, 2 mg/kg of IKK-NBD peptide (Enzo Life Sciences) for NFκB, 200 mg/kg 
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Sodium Salicylate (Calbiochem) for NFκB or the respective vehicle, 24 and 5 hours 
prior to PBS or LPS administration.  
 
BrdU labeling and retention 
WT or mixed BM chimeric mice were i.p. injected with 9 mg/kg BrdU and 
subsequently put on drinking water containing 800 μg/ml BrdU and 5% sucrose for 
two weeks with refreshing the water every 2-3 days. Then drinking water was 
switched to normal water for another two weeks until analysis. While given normal 
drinking water, animals were treated with PBS or LPS, together with or without 
inhibitors as described above. One week after final PBS or LPS injections, BM cells 
were harvested and subjected to cell surface staining with antibodies against lineage 
markers above, and to intracellular anti-BrdU staining with an APC conjugated 
antibody according to the manufacturer’s instructions (BD bioscience). BrdU positivity 
was determined by measuring baseline intensity using non-BrdU treated BM, stained 
with the anti-BrdU antibody. 
 
Detection of ROS and p38 activation 
HSCs (LKS CD34-CD150+), MPPs (LKS CD34+), and CMPs/GMPs (LK CD34+) were 
sorted from BM of WT mice that were treated with PBS or 50 μg LPS 16 hours 
before, and incubated with 10 μM DCF-DA (Life technologies) for 30 min at 37°C, 
followed by fixation with 2% PFA for 10 min. After permeabilization with 0.1% Triton 
X-100 (Roche)/PBS for 20 min and blocking with 0.1% Triton X-100/PBS containing 
10% goat serum (DAKO) for an hour, the cells were stained with anti-phospho p38 
(Cell signaling) and detected by goat anti-rabbit AlexaFluor 488 (Life Technologies). 
Cells were analyzed on a FACS Canto II, and positivity for each marker was 
determined based on the intensity of PBS-treated cells that were stained with both 
markers. 
 
CFSE labeling and chasing 
WT HSCs (3,000-7,835 LKS CD34-CD48-CD41-CD150+ cells) or MPPs (113,250 LKS 
CD34+ cells) were isolated from B6/J mice (CD45.1+), labeled with CFSE as 
previously described (Takizawa JEM 2011) and i.v. transferred into Tlr4-/- mice 
(CD45.1+) without irradiation. Two or three days after mice were treated with PBS or 
100 μg LPS for 2 or 3 times and were analyzed on day 6 for HSCs and MPPs. 
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Immunocytochemistry 
HSC (LKS CD34-CD48-CD41-CD150+) and LK CD34-CD48-CD41- cells were sorted 
from BM of WT mice at 3 or 14 days after i.p. injection of PBS or 50 μg LPS for 8 or 
12 times, and plated on a glass slide, coated with 0.01% poly-L-lysine (Sigma 
Aldrich), followed by 60 min incubation at R.T (Room Temperature) to let cells settle 
down on the slide. Cells were then fixed with 4% PFA for 10 min and permeabilized 
with 0.5% Triton X-100 (Roche)/PBS for 20 min and blocked with 0.5% Triton X-
100/PBS containing 10% goat serum (DAKO) for one hour or overnight. Anti-
phospho-histone H2AX (JBW301, Millipore) staining was done overnight at 4°C, and 
subsequently binding was visualized with a goat anti-mouse AlexaFluor 647 (Life 
Technologies) for the respective primary antibodies. Nuclei were counterstained with 
DAPI (Life Technologies) and images were taken on a Leica SP5 with a 63x objective 
lens (Leica). The number of phosphor-H2AX positive foci was counted manually on 
image software, Imaris (Bitplane, USA). 
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Abstract (200 words allowed) 
Hematopoietic stem cells (HSCs) are maintained in a so-called bone marrow (BM) 
niche, which is a specialized environment that provides factors for their maintenance. 
While the cellular and molecular components of the mouse BM niche have been 
studied extensively, little is known about the human BM niche components. We have 
previously shown with a developmental tissue engineering approach that human 
adult BM mesenchymal stromal cells (MSCs) can ex vivo generate a human cartilage 
template and to in vivo develop human bone organs, so called “ossicles”. However, it 
has not been tested whether the human bone organs derived from MSCs can 
function as niche for human HSC maintenance. Upon in vivo implantation of the 
human ossicles into immunodeficient mice and engraftment of human CD34+ cells, 
we show an efficient development of human hematopoiesis with phenotypic HSCs in 
the human ossicles. Functional assays show a better maintenance of human 
hematopoietic stem and progenitors within the human ossicles compared to mouse 
bone marrow, proving that the human ossicle can serve as a functional human BM 
niche. The engineering of a heterotrophic human BM niche that is transplantable and 
re-engineerable can serve as a platform that allows the study of human 
hematopoiesis in an optimized environment in vivo. 
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Introduction 
 
Lifelong self-renewal and multilineage repopulation capacity of hematopoietic stem 
cells (HSCs) is maintained in a specialized microenvironment in the bone marrow 
(BM), the so-called “niche” that provides HSCs with vital factors for their 
maintenance. Besides the hematopoietic cells, the BM microenvironment is 
composed of a complex network of cells, such as adipocytes35, osteoblast/osteoclast 
cells36-39, megakaryocytes33,34,133 and endothelial cells40,41,45, macrophages31,32,45 and 
Schwann cells42, as well as specialized stromal cells as e.g. Nestin-positive 
mesenchymal stromal cells (MSCs)43, CXCL12 abundant reticular cells (CARs)44,45,47, 
and leptin receptor-positive cells (LepR+ cells)45. However, little is known about the 
cellular and molecular components of the human BM niche. In recent years the field 
has taken great leaps in engineering the BM microenvironment by genetic 
modification of animals as mice. This approach has some limitations e.g., it is time-
consuming, results usually in one modification at a time and is restricted to mice or 
surrogate organisms that do not necessarily reflect the human situation. As MSCs 
are able to differentiate into chondrocytes through endochondral ossification, they are 
used as a source to form bone marrow microenvironment in vivo95. Several studies 
have suggested that upon subcutaneous implantation of mouse or human MSCs into 
immune-deficient mice they are able to form a supportive bone marrow cavity through 
a vascularized cartilage intermediate which was replaced by hematopoietic tissue 
and bone and that can attract and support murine hematopoiesis93,97-99. Nevertheless 
there is a lack of in vivo models that can recapitulate the complexity of a human BM 
environment to support normal and malignant hematopoiesis. Thus, the current 
xenotransplant mouse models are not able to reproduce the physiological 
interactions between HSCs and a human BM microenvironment as human HSCs are 
engrafted in a mouse BM microenvironment. A recent study has shown that only 
human BM-derived MSCs are able to form a bone marrow cavity through a 
vascularized cartilage intermediate100, which can maintain murine long-term HSCs as 
well as functional human HSCs defined as CD34+CD38-CD90+CD45RA+ after cord 
blood transplantation101. Most of the recent developmental tissue engineering 
protocols 55 do not or only in a small amount show the mineralization of the newly 
formed tissue, which does not mimic a fully regenerated bone organ. Recently we 
reported a tissue engineering protocol where human adult BM-derived mesenchymal 
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stromal cells (MSCs) are ex vivo differentiated into hypertrophic cartilage, and, upon 
in vivo implantation into immunodeficient mice, develop to a fully mature bone organ, 
so called „ossicle“, via endochondral ossification99. We hypothesize that these 
ossicles provide a sufficient engraftment and maintanance of human hematopoiesis 
in a xenocraft mouse model. 
Here we show that indeed human ossicles can serve as a niche that can better 
maintain functional human Hematopoietic stem cells (HSC) compared to the mouse 
BM of immune-compromised hTPOhSIRP mice. 
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Material and Methods 
Mice 
The human TPO knock-in replacement was performed by using  Velocigene 
Technology , as reported previously134. Human SIRPα expression was achieved by 
transgenesis using a BAC in the same genetic background, as previously 
described135. These two mouse strains were intercrossed to generate Balb/c Rag2 
IL2-/- cγ-/- hTPOKI hSIRPαTg mice (STRG). All mice were maintained at the University 
Hospital Zurich animal facility according to the guidelines of the Swiss Federal 
Veterinary Office, and all the experiments were approved by the Veterinäramt of 
Kanton Zurich, Zurich, Switzerland. 
 
MSC isolation, in vitro culture, and in vivo implantation. 
Human mesenchymal stem cells (MSCs) were isolated from human bone marrow 
aspirates and processed as previously reported99. Shortly, MSCs were expanded for 
maximum four passages and seeded onto type I collagen meshes (8-mm-diameter, 
2-mm-thick disks; Ultrafoam, Davol) at a density of 70×106cells/cm3 and cultured in a 
serum-free chondrogenic medium for 3 weeks, followed by 2 wk in a serum-free 
hypertrophic medium, supplemented with 50 nM thyroxine, 7.0 ×10−3M β-
glycerophosphate, 10−8M dexamethasone, and 2.5×10−4M ascorbic acid and IL-1β 
(50 pg/mL). The resultant human cartilage templates were implanted in s.c. pouches 
on the back of 6-10 week old Balb/c Rag2 IL2-/- cγ-/- hTPOKI hSIRPαTg mice (four 
samples per mouse ). 
 
Human progenitor cell isolation and injection 
Human CD34+ cells were purified from cord blood by density gradient centrifugation 
followed by positive immunomagnetic selection with anti-human CD34 microbeads 
(Miltenyi Biotec). Cells were frozen in FBS containing 10% DMSO and kept in liquid 
nitrogen. All human studies were approved by the Cantonal ethics committee of 
Zurich, Switzerland. Four weeks after ossicle implantation, hTPOhSIRP mice were 
sublethally irradiated (400 cGy) and 6-8x105 CD34+ cells pooled from several donors 
were injected intravenously, followed by analysis at 8 weeks after transplantation.  
 
Flow cytometry 
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Mice were euthanized, and vascularized ossicle as well as mouse Femur and Tibia 
were removed.  Explanted human ossicle and mouse bone were crushed using a 
mortal and pestle, digested at 37°C for 45 min in DMEM (Invitrogen), 10% FCS 
(Invitrogen), 10mM HEPES (Invitrogen), 0.4% collagenase II (Worthington) and 
0.02% DNase I (Worthington) and washed with PBS containing 2% human Serum 
and then filtered on a 70 μm cell strainer. The resultant cells were incubated with 
human and mouse FcR blocking antibodies (Miltenyi Biotec) and stained with TRI-
COLOR conjugated human lineage antibodies (CD2, CD3, CD4, CD8, CD10, CD11b, 
CD14, CD19, CD20, CD56, CD235a; Invitrogen), human CD45-eFluor 450 (clone 
HI30, eBioscience), human CD90-PE (clone 5E10, Beckton Dickinson (BD)), human 
CD38-FITC (clone HIT2, BD), human CD34-PECy7 (clone 8G12, BD), human 
CD45RA-APC eFluor 780 (clone HI100, eBioscience) and mouse CD45.2-APC 
(clone 104, Biolegend). Multi-lineage engraftment in peripheral blood (PB) and cells 
from human ossicle and mouse bone, was detected by human CD3-PECy7 (clone 
UCHT1, eBioscience), human CD19-APCCy7 (clone HIB19, BD) and human CD33-
APC (clone P67.6, BD), human CD45-eFluor 450 (clone HI30, eBioscience) and 
mouse CD45.2-FITC (clone 104, eBioscience). Propidium Iodide (Invitrogen) was 
added to the samples to exclude dead cells. All samples were analyzed on a FACS 
Aria III (BD Biosciences) or LSR Fortessa (BD Biosciences). 
 
CFU and Serial transplantation 
For the colony-forming assay, 1000 hCD45+hlin-hCD34+ cells were sorted from 
ossicle and femur bone marrow, respectively, and plated onto methylcellulose 
medium (Stem Cell Technologies) containing 100 ng/ml hIL-3, 50 ng/ml hIL-6, 50 
ng/ml hIL-11, 50 ng/ml hSCF, 250 ng/ml hTPO, 20 U/ml hEPO, 250 ng/ml hGM-CSF 
and 50 ng/ml hFlt3L. Cultures were maintained at 37°C in 5% CO2 and scored after 
12-14 days.  
  For serial transplantation, 4 x105 CD34+ cells from ossicle and femur bone marrow 
were serially transplanted into sublethally irradiated hTPOhSIRP mice, followed by 
monthly PB and terminal BM analysis for human engraftment. 
 
Cell cycle analysis assay 
Single cell suspensions from human ossicle and mouse bone were first stained with 
TRI-COLOR conjugated lineage antibodies, human CD45-BV711 (clone HI30, 
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Biolegend), mouse CD45-BV786 (clone 30-F11, Biolegend), human CD90-FITC 
(clone 5E10, BD), human CD38-APC (clone HIT2, BD), human CD34-PECy7 (clone 
8G12, BD), human CD45RA-APC eFluor 780 (clone HI100, eBioscience) to detect 
human hematopoiesis. After washing with PBS containing 2% human Serum cells 
were fixed with Fixation/Permeabilization buffer (eBioscience) for 30min at 4°C. Cells 
were then stained with PE-anti Ki67(dilution 1:5, BD) for 45 min at room temperature 
in Permeabilization buffer (eBioscience). After washing, cells were stained with DAPI 
(1mg/ml, Invitrogen) for 30 min at 4 °C and immediately analysed on a LSR Fortessa 
(BD Biosciences). 
 
Histological Staining 
Samples were embedded in paraffin and sections of 5 μm thickness prepared using a 
microtome. Safranin-O, Alizarin red, hematoxylin/eosin and Masson tri-chrome 
staining were performed as published previously99. 
  
Microtomography 
Samples were collected and fixed overnight in 1.5% formaldehyde at 4°C. 
Microtomography of the explants was performed using a tungsten x-ray source at 70 
kV and 260 μA with an aluminum filter of 0.5 mm (Nanotome, GE, USA). 
Transmission images were acquired for 360° with an incremental step size of 0.25°. 
Volumes were reconstructed using a modified Feldkamp algorithm (software supplied 
by manufacturer) at a voxel size of 2.5-3 μm. Thresholding, segmentation and 3D 
measurements were performed using the VGStudio Max software. After 
microtomography, samples were decalcified in 15% EDTA solution (Sigma Aldrich) 
before histology. 
 
Statistical analysis 
All data are shown as the mean, unless indicated otherwise. All statistical 
comparisons were evaluated with Students t-Test; *p<0.05; **p<0.01; ***p<0.001 
(two-tailed t-test). 
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Results and Discussion 
Human hematopoiesis is maintained in engineered human ossicles 
Human ossicles were generated as described previously99 and implanted 
subcutaneously in the back of immune-compromised mice (hTPhSIRP). Four weeks 
after implantation, mice were irradiated and transplanted with human cord-blood 
(CB)-derived CD34+ cells. After 2 months, the engraftment of human HSPCs was 
analyzed in the human ossicle and mouse bone of the implanted mice by flow 
cytometry (Figure 1A).  
  Upon in vivo implantation, the hypertrophic cartilage underwent extensive 
remodeling. Hypertrophic cartilage areas are replaced by BM and bone at increasing 
densities of mineralization and the central construct core is filled with matrix that 
remodels to trabecular-like bone structures (Supplemental Figure 1). Human ossicles 
show efficient vascularization as indicated by reddish color (Figure 1B), suggesting 
homing of cells through peripheral blood circulation. Histological and micro-CT 
analysis confirms that the human ossicle has morphological and structural similarities 
to naive bone tissue. 
  Two months after reconstitution with human CB-derived CD34+ cells, we identified 
mature T cells, myeloid cells, B cells as well as immature B cells, Pro and Pre B cells 
in the human ossicles (Figure 1 C). As already shown in previous studies101 the 
majority of B cells were immature B cells. Besides human mature cell engraftment we 
also detected human HSCs (CD34+CD38-CD90+CD45RA-), multipotent progenitor 
cells (MPP, CD34+CD38-CD90-CD45RA-) and multilymphoid progenitors (MLP, 
CD34+CD38-CD90+CD45RA+) within the HSPC compartment (CD34+CD38-), as 
well as common myeloid progenitors, megakaryocyte/erythrocyte progenitors 
(CMP/MEP, CD34+CD38+CD45RA-) and granulocyte/macrophage progenitors 
(GMP, CD34+CD38+CD45RA+) within the Myeloid progenitors compartment (MyelP, 
CD34+CD38+) in all human ossicles analyzed (Figure 1D and E). Interestingly we 
found a significant lower engraftment of myeloid progenitors including GMPs within 
the human ossicle niche. Although we did not observe a significant difference in the 
engraftment of human hematopoietic stem and progenitor cells in the human ossicles 
compared to the mouse bone the fold change of the frequency within one mouse 
showed a higher frequency of HSPCs, MPPs, HSCs, MLPs and a significant lower 
frequency of Myeloid Progenitors and GMPs within the human ossicle (Figure 1F).  
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Human ossicle niche maintains human HSPC quiescence 
In mouse, mouse HSCs become quiescent through the interaction with the 
surrounding niche. In contrast, human HSCs in a xenograft mouse model are highly 
proliferative136, suggesting that the mouse niche does not support human HSC 
quiescence. To investigate whether the human ossicle can provide a human HSC 
niche that's drives them towards quiescence, we performed a cell cycle analysis of 
HSPCs within the human ossicle and the mouse bone. We observed that overall less 
than 5 % of Hematopoietic cells are quiescent compared to CB-MNC with up to 90% 
quiescent cells (Figure 2A). Nevertheless, there is a tendency that HSPCs, MyelP, 
HSCs and MLPs are more quiescent in the human ossicle compared to the mouse 
bone (Figure 2B). Interestingly more than 50% of HSCs are in S-G2-M phase 
whereas only 10 % of HSPCs, MyelP, MPPs and MLPs are in S-G2-M phase 
(Supplementary Figure 3). These results suggest that HSPC as well as MyelP 
become more quiescent through the interaction with the human ossicle niche.  
 
Functional, self-renewing human HSPCs are maintained in human ossicle 
Finally, to investigate if HSPCs that are maintained in the human ossicles are also 
functional, we first performed a Myeloid-colony forming unit (CFU) assay. Out of 1000 
plated hCD45+hlin-hCD34+ from mouse bone and human ossicle, the cells from the 
human ossicle gave rise to significant more myeloid colonies compared to the once 
from the mouse bone. This suggests that there is a higher frequency of functional 
hematopoietic stem and progenitor cells maintained in human ossicles. 
  Furthermore, to confirm the presence of functional, self-renewing human HSPCs in 
human ossicle, secondary transplantation was performed. We isolated hCD34+ cells 
from mouse bone and human ossicle and transplanted them separately in sublethal 
irradiated secondary recipients (Figure 2D). After 8 weeks we observed a tendencial 
higher engraftment of hCD45+ cells in mice transplanted with hCD34+ cells derived 
from the human ossicle. Interestingly, human ossicle derived CD34+ cells tended to 
give higher engraftment compared to mouse bone-derived CD34+ cells. At 8 weeks 
after transplantation, we identified mature B cells, T cells and significant higher levels 
of Myeloid cells from the human ossicle derived CD34+ cells (Figure 2E). Further, 
hematopoietic stem and progenitor cells (HSPCs, HSC, MPP and MLP) as well as 
Myeloid Progenitors (MyelP, CMP/MEP and GMP) derived from human ossicle show 
a better engraftment than mouse bone derived human HSPCs and MyelP (Figure 
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2E). This data suggests that the human ossicle provide a better niche to maintain 
functional and self-renewing human HSPCs as the mouse bone of immune-
compromised mice.  
 
It was shown that human MSCs are able to undergo in vivo endochondral ossification 
and are able to build a cavity that supports host derived hematopoietic cells in 
immunocompromised mouse models. Nevertheless the long standing question is, if 
these human bone organs can also support human hematopoiesis. In this study we 
show an ossicle model system that can serve as a niche to maintain human 
hematopoietic stem cell activity more efficient than existing xenocraft models. We 
used a standardized and reproducible in vitro protocol, that allows an in-process 
control of the hypertrophic cartiladge before implantation into hTPOhSIRP mice. The 
human bone organ model was engineered by activation of hMSCs in vitro towards an 
endochondral ossification. At 12 weeks after implantation we could observe a 
selforganized progression of the process, leading to bone development and efficient 
vascularization and finally into a functional hematopoietic niche. Nevertheless, further 
studies are required to validate origin (human/mouse) of the functional niche cells. 
We showed that human HSPCs injected into the peripheral blood circulation home to 
human ossicles after whole body subleathal irradiation, suggesting that human 
HSPCs can migrate in and out of ossicles similar to long bone. However, the impact 
of irradiation on the newly generated human bone needs to be determined. After 
irradiation, a stable engraftment of human CD45+ cells was observed in mouse bone 
and human ossicle. Both lympohiod and myeloid lineage cells were observed by 
FACS analysis. Interestingly we found that the frequency of myeloid progenitors is 
less within the human ossicle. In our model, human HSPCs were found to be slightly 
more quiescent in the human ossicle suggesting that human ossicle are more similar 
to a human HSC niche than the mouse bone. However no statistical significance was 
defermined. The most recognized assay to prove functional HSCs activity is the long-
term reconstitution assay. In our study we could show that ossicle derived human 
CD34+ cells show a better reconstitution activity (significant more myeloid cells) 
compared to mouse bone derived human CD34+ cells. These results were confirmed 
by a significant better CFU-activtiy of ossicle derived human CD34+ compared to 
mouse bone derived human CD34+ cells. Some of the previous ossicle studies lack 
these functional assay. Reinisch et. Al., could show secondary engraftment of ossicle 
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derived human HSPCs only in one recipient transplanted with ossicle but not in non-
ossicle NSG mice.  
Most of our understanding of the BM niche and the interaction of HSCs with its 
environment comes from mouse studies, whereas little is know about human HSCs 
and their environment, because of the lack of models that mimic the human BM 
microenvironment. Several studies suggest that human ossicle models can be 
succefully engrafted with human Leukemia cells and therefore could be used as a 
modelt o evaluate anti-leukemia drugs101. There is increasing evidence that leukemia 
development is dependent on cellular interactions with the BM niches137. As our 
model mimics a more closly the human niche it could be used to study the effect of 
the BM microenvironment on leukemia development and progression.  
Here we suggest a human bone organ model that more closely resembles a human 
bone organ and is able to maintain functional human HSCs. Therefore the system 
can be used to study human healthy as well as malignant hematopoiesis in its 
environment that can be genetically engineered (e.g. knockin out or overexpression 
of specific niche factors) and used for therapeutic purposes. 
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Figure 1 Human bone organ can maintain phenotypic human hematopoietic 
stem cells. (A) Experimental outline: Human Bone marrow-Mesenchymal stem cells 
(BM-MSCs) where cultured on a collagen scaffold for 5 weeks under chondrogenic 
and hypertrophic conditions. The hypertrophic cartilage was implanted subcutaneous 
into Balb/c Rag2 IL2-/- cγ-/- hTPOKI hSIRPαTg mice (hTPOhSIRP). 4 weeks post 
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implantation, sublethal irradiated mice carrying ossicles were transplanted with 
human Cord blood (CB) derived CD34+ cells. After 8 weeks, cells were harvested 
from human ossicles and mouse bone and analyzed. (B) representative photograph 
of human ossicle and mouse bone (Femur and Tibia) at 12 weeks post implatation 
(milimeter scale is shown). The human ossicle are filled with blood as indicated by 
their red color. (C) Summary of cytofluorimetric analysis of mature cells. Lympohid 
progenitors (hCD45+hCD3-hCD33-hCD19-hCD5-), T cells (hCD45+hCD3+), Myeloid 
cells (hCD45+hCD33+), mature B cells (hCD45+hCD3-hCD33-hCD19+hCD5+), 
immature B cells (hCD45+hCD3-hCD33-hCD19+hCD5-), Pre B cells (hCD45+hCD3-
hCD33-hCD19+hCD5-hCD10+hCD34-) and Pro B cells (hCD45+hCD3-hCD33-
hCD19+hCD5-hCD10+hCD34+). Statistical analysis showed no significance. Bar 
graphs represent means (n =5). (D) Representative profile of HSCs and progenitors 
in mouse bone and in vivo-remodeled human ossicles 8 weeks after transplantation 
of human CB-derived CD34+ cells. (E) Summary of cytofluorimetric analysis of BM 
HSCs and progenitors (n =14). Engraftment >10% hCD45+ cells. Statistical 
significance was determined with students T-Test, *P<0.05. Bar graphs represent 
means. (F) Fold change of HSCs and Progenitors in human ossicle compared to 
mouse bone. Bar graphs represent means + s.e.m. (n =14). Statistical significance 
was determined with students T-Test, *P<0.05. 
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Figure 2 Maintenance of functional human HSCs in the implanted human bone 
organ. (A) Representative profile of cell cycle analysis of human HSCs and 
progenitors in mouse bone and human ossicle. (B) Summary of cytofluorimetric 
analysis of cell cycle status of HSCs and progenitors in mouse bone and human 
ossicle 8 weeks after transplantation of human CD34+ cells (n=5). (C) Number of 
CFUs (colony-forming cells) in 1000 plated hCD45+lin-CD34+ cells. Distribution of 
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myeloid colony subtypes on day 14 . CFU, colony-forming unit; GEMM (granulocyte, 
erythrocyte, macrophage, megakaryocyte); Mk, megakaryocyte; E, erythrocyte; GM, 
granulocyte and macrophage; G or M, granulocyte or macrophage. Bar graphs show 
data from two independent experiments, n=9 ; Statistical significance was determined 
with two-way ANOVA, *P<0.05. (D) Experimental outline: Human bone organs were 
engineered and implated as decribed before. 8 weeks after transplantation of human 
CD34+ (1st Tx), cells from mouse bone and human ossicle were harvested, enriched 
for human CD34+ cells and transplanted into sublethal irradiated hTPOhSIRP mice 
(2nd Tx). (E) Summary of secondary engraftment of human CD34+ HSPC in mouse 
BM. Purified human CD34+ cells derived from engrafted ossicle and mouse bone 
were transplanted into sublethal irradiated recipient mice (n=4 from each) and 
analyzed 8 weeks after transplantation. Statistical significance was determined with 
students T-test, *P<0.05. Bar graphs represent means. 
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Supplemental Figures 
 
 
 
Supplemental Figure 1 Characterization of in vitro and in vivo bone tissue formation. 
(A) Representative sections (Safranin O, H&E and Masson’s Trichrome) and 3D 
reconstructed microtomographic (μCT) images of samples after 5 weeks in vitro 
culture, 4 weeks after implantation into hTPOhSIRP mice and 12 weeks after 
implantation (8 weeks after CB CD34+ transplantation). Scale bar 1mm. (B) 
Quantitative histomorphometric data (n=9) of the total volume of the ossicle (TV) as 
well as the bone volume within an ossicle (BV) and its ratio (BV/TV). The trabecular 
bone number (TbN) representing the average number of trabeculae per unit length, 
their average thickness (TbTh) as well as the mean distance between the trabeculae 
(TbSp) is represented on the lower graphs.  
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Supplemental Figure 2 Mature and Human hematopoietic stem and progenitor cells 
in Cord blood Mononuclear cells. (A) FACS analysis showing the distribution of 
human mature cells in CB-Mononuclear cells (MNC). Human CD45+ alive cells are 
gated for mature T cells (hCD45+hCD3+hCD33-) and Myeloid cells (hCD45+hCD3-
hCD33+). B cells are divided in mature (hCD45+hCD3-hCD33-hCD19+hCD5+) and 
immature B cells (hCD45+hCD3-hCD33-hCD19+hCD5-) with Pre (hCD45+hCD3-
hCD33-hCD19+hCD5-hCD34-hCD10+) and Pro B cells (hCD45+hCD3-hCD33-
hCD19+hCD5-hCD34+hCD10+). (B) FACS analysis showing the distribution of 
human hematopoietic cells in CB-MNC. Human CD45+, lineage – alive cells are 
gated for hematopoietic stem and progenitors cells (CD34+CD38-, HSPC) and 
myeloid Progenitors (CD34+CD38-, MyelP). HSPCs are further subdivided based on 
CD90 and CD45RA expression into hematopoietic cells (HSC, CD90+CD45RA-), 
multipotent progenitors (MPP, CD90-CD45RA-) and lymphoid-primed multipotent 
progenitors (LMPP, CD90+CD45RA+), whereas MyelP are subdivided into common 
myeloid progenitors and megakaryocyte erythroid progenitors (CMP and MEP, 
CD34+CD45RA-) and granulocyte macrophage progenitors (GMP, 
CD34+CD45RA+). 
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Supplemental Figure 3 Full cell cycle analysis of Hematopoietic stem and progenitor 
cells from human ossicle and mouse bone. Percentage of each cell cycle phase (G0, 
G1 and S/G2/M) of HSCs and progenitors from human ossicle and mouse bone 8 
weeks after transplantation of human CB-derived CD34+ cells.  
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a) Research article (in preparation) 
 
Developmental engineering of customized human hematopoietic organs 
 
Paul Bourgine1, Kristin Fritsch2, Sébastien Pigeot3, Ivan Martin3, Markus G. Manz2, 
Hitoshi Takizawa4, Timm Schroeder1 
 
1Department of Biosystems Science and Engineering, ETH Zurich;  
2Division of Hematology, University Hospital Zurich and University of Zurich;  
3Department of Biomedicine and Surgery, University Hospital Basel;  
4International Research Center for Medical Sciences, Kumamoto University 
 
This is a project that is based on research article 2 and is an ongoing collaboration 
with Prof. Timm Schroeder and Prof. Ivan Martin. In this paper I contributed as co-
first author.  
 
Abstract 
Human Hematopoietic Stem Cells (hHSC) are responsible for the continuous and 
lifelong replenishment of blood and immune cells. In adult, hHSC reside in the bone 
marrow (BM) niche, a unique microenvironment tightly orchestrating hHSC functions. 
However, primary knowledge on the cellular and molecular composition of the human 
BM niche remains cryptic. Existing insights are predominantly derived from murine 
studies that do not fully reflect the human system. Here, we report the successful 
engineering of humanized BM niches as a platform to study human hematopoiesis. 
Human mesenchymal stromal cells (hMSC) are primed toward developmental 
program in order to form ectopic bone organs in mice. The resulting human ossicles 
(hOss) host a human hematopoietic compartment, but also comprised human niche 
cells derived from the implanted hMSC. In fact, hMSC can be used as cellular vector 
for the delivery of factors influencing human blood development. Exemplified by the 
targeted SDF1α delivery, the present study demonstrates the feasibility to design 
customized humanized hematopoietic organs. The established method is expected to 
allow gathering human-specific findings of higher translational relevance. 
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b) Review article (Published: Frontiers in Immunology 2016 Volume 7:502) 
 
 
Inflamm-Ageing of Hematopoiesis and Hematopoietic Stem Cells 
 
Larisa V. Kovtonyuk1*, Kristin Fritsch1*, Markus G. Manz1, Hitoshi Takizawa1,2 
 
1Division of Hematology, University Hospital Zurich and University of Zurich, CH8091 
Zurich, Switzerland 
2International Research Center for Medical Sciences, Kumamoto 860-0811, Japan 
* These authors contributed equally, co-first authors 
 
This is an on topic review, which I contributed as a co-first author. I was responsible 
for the inflammation part of this paper. 
 
Abstract 
All hematopoietic and immune cells are continuously generated by hematopoietic 
stem cells (HSCs) and hematopoietic progenitor cells (HPCs) through highly 
organized process of stepwise lineage commitment. In the steady state, HSCs are 
mostly quiescent, while HPCs are actively proliferating and contributing to daily 
hematopoiesis. In response to hematopoietic challenges, e.g., life-threatening blood 
loss, infection, and inflammation, HSCs can be activated to proliferate and engage in 
blood formation. The HSC activation induced by hematopoietic demand is mediated 
by direct or indirect sensing mechanisms involving pattern recognition receptors or 
cytokine/chemokine receptors. In contrast to the hematopoietic challenges with 
obvious clinical symptoms, how the aging process, which involves low-grade chronic 
inflammation, impacts hematopoiesis remains undefined. Herein, we summarize 
recent findings pertaining to functional alternations of hematopoiesis, HSCs, and the 
bone marrow (BM) microenvironment during the processes of aging and inflammation 
and highlight some common cellular and molecular changes during the processes 
that influence hematopoiesis and its cells of origin, HSCs and HPCs, as well as the 
BM microenvironment. We also discuss how age-dependent alterations of the 
immune system lead to subclinical inflammatory states and how inflammatory 
signaling might be involved in hematopoietic aging. Our aim is to present evidence 
supporting the concept of "Inflamm-Aging," or inflammation-associated aging of 
hematopoiesis.  
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c) Review article (Published: Haematologica 2016 Volume 101(1):5-19) 
 
Humanized hemato-lymphoid system mice 
 
Alexandre P.A. Theocharides1, Anthony Rongvaux2, Kristin Fritsch1, Richard A. 
Flavell2, and Markus G. Manz1 
 
1Hematology, University Hospital Zurich and University of Zurich, 8091 Zurich, 
Switzerland 
2Department of Immunobiology and Howard Hughes Medical Institute,Yale University 
School of Medicine, New Haven, CT, USA 
 
This is an on topic review, which I was a contributing author.  
 
Abstract 
Over the last decades, incrementally improved xenograft mouse models, supporting 
the engraftment and development of a human hemato-lymphoid system, have been 
developed and now represent an important research tool in the field. The most 
significant contributions made by means of humanized mice are the identification of 
normal and leukemic hematopoietic stem cells, the characterization of the human 
hematopoietic hierarchy, and their use as preclinical therapy models for malignant 
hematopoietic disorders. Successful xenotransplantation depends on three major 
factors: tolerance by the mouse host, correct spatial location, and appropriately 
cross-reactive support and interaction factors such as cytokines and major 
histocompatibility complex molecules. Each of these can be modified. Experimental 
approaches include the genetic modification of mice to faithfully express human 
support factors as non-cross-reactive cytokines, to create free niche space, the co-
transplantation of human mesenchymal stem cells, the implantation of humanized 
ossicles or other stroma, and the implantation of human thymic tissue. Besides the 
source of hematopoietic cells, the conditioning regimen and the route of 
transplantation also significantly affect human hematopoietic development in vivo. 
We review here the achievements, most recent developments, and the remaining 
challenges in the generation of pre-clinically-predictive systems for human 
hematology and immunology, closely resembling the human situation in a 
xenogeneic mouse environment.  
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d) Research article (Published: Blood 2016 Volume 128(18):2253-2257) 
 
MPL EXPRESSION ON AML BLASTS PREDICTS PERIPHERAL BLOOD  
NEUTROPENIA AND THROMBOCYTOPENIA  
 
Philipp J. Rauch1,2, Jana M. Ellegast1, Corinne C. Widmer1, Kristin Fritsch1, Jeroen 
S. Goede1, Peter J.M. Valk3, Bob Löwenberg3, Hitoshi Takizawa1,4, & Markus G. 
Manz1 
 
1Division of Hematology, University Hospital and University of Zurich, Zurich,  
Switzerland;  
2Department of Medicine, Boston University School of Medicine, Boston, MA;  
3Department of Hematology, Erasmus University Medical Center, Rotterdam, The  
Netherlands  
4International Research Center for Medical Sciences, Kumamoto University, 
Kumamoto 860-0811, Japan 
 
I am a contributing author. My contribution was to perform some flowcytometry 
experiments and real-time PCR.  
 
Abstract 
Although the molecular pathways that cause acute myeloid leukemia (AML) are 
increasingly well understood, the pathogenesis of peripheral blood cytopenia, a major 
cause of AML mortality, remains obscure. A prevailing assumption states that AML 
spatially displaces nonleukemic hematopoiesis from the bone marrow. However, 
examining an initial cohort of 223 AML patients, we found no correlation between 
bone marrow blast content and cytopenia, questioning the displacement theory. 
Measuring serum concentration of thrombopoietin (TPO), a key regulator of 
hematopoietic stem cells and megakaryocytes, revealed loss of physiologic negative 
correlation with platelet count in AML cases with blasts expressing MPL, the 
thrombopoietin (scavenging) receptor. Mechanistic studies demonstrated that MPLhi 
blasts could indeed clear TPO, likely therefore leading to insufficient cytokine levels 
for nonleukemic hematopoiesis. Microarray analysis in an independent multicenter 
study cohort of 437 AML cases validated MPL expression as a central predictor of 
thrombocytopenia and neutropenia in AML. Moreover, t(8;21) AML cases 
 83 
demonstrated the highest average MPL expression and lowest average platelet and 
absolute neutrophil counts among subgroups. Our work thus explains the 
pathophysiology of peripheral blood cytopenia in a relevant number of AML cases. 
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DISCUSSION AND OUTLOOK 
 
Hematopoietic homeostasis in steady-state and during hematopoietic challenge is 
maintained by lifelong self-renewing HSCs in the BM. Recent findings have indicated 
that not only peripheral mature immune cells but also HSCs in BM can respond to 
infection by sensing pathogen-associated molecular patterns (PAMPs) through 
pattern recognition receptors (PRR) or to pro-inflammatory cytokines through 
respective cytokine receptors. However, little is known about its impact on function of 
lifelong self-renewing HSCs in the BM. In the first part of my thesis I examine how 
bacterial infection alters HSC functions, and the underlying molecular mechanism, by 
in vivo systematic challenge of LPS, a gram-negative bacterial component, 
recognized by TLR4. The activation of TLR4 via MyD88 or TRIF pathways during 
bacterial infection is very well studied in immune cells138. However, their role in 
regulating the BM response during infection or inflammation is poorly understood. 
Our study shows that in mixed BM chimeric mice a direct activation of TLR4 limits 
competitive repopulating ability of HSCs via TRIF- but not MYD88-mediated 
pathways, and increases divisional history and DNA damage and repair responses in 
HSCs. Pharmacological inhibition of p38 mitogen activated protein kinase (MAPK14) 
and reactive oxygen species (ROS) rescued HSC dysfunction. This data shows 
evidence that in vivo LPS directly activates BM resident HSC via a TLR4-TRIF-ROS-
p38 mediated pathway, and results in limiting their competitive self-renewal possibly 
through increased divisional history and DNA damage. In line with our study, Zhang 
et. al.139 confirmed that HSCs function is altered during sepsis in an TLR4-TRIF 
dependent manner. However, they also suggest that MYD88 plays a dominant role in 
myelosuppression during sepsis. This finding points out that MyD88 and TRIF can 
occur as two independent processes with cell-specific effects. Another study showed 
that a depletion of p38α in HSPCs leads to defective cell-cycle progression during 
hematopoietic stress140. This might suggests that p38α activation upon LPS 
stimulation leads to increased cell-cycle activity and finally to proliferation of HSPCs.  
Our as well as other studies suggest that systemic infection might cause 
accumulation of genetic events in HSCs that might lead to HSC deficiency or even to 
malignant transformation and eventually development of leukemia. In humans, there 
has been evidences that an increased history of infections or autoimmune diseases 
lead to a higher risk to develop leukemia later in life65. However, most mutations 
occur with DNA replication during cell division which does not ressecary lead to blood 
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cancer. One might speculate that in a steady-state environment, these genetically 
altered HSCs might be removed from the HSC pool or corrected at the DNA level by 
naturally existing surveillance mechanisms (e.g., apoptosis or DNA repair 
machinery). A minimum of two to three driver mutations are needed for the 
development of leukemia. So far it is unknown how mutations that occur during 
normal hematopoiesis relate to mutations that initiate cancer. We hypothesize that in 
chronic inflammatory conditions genetically altered HSCs might escape from the 
normal regulatory mechanisms, i.e. the mutated HSC clones might survive and 
accumulate further critical genetic events. To prove this hypothesis I have started to 
establish clonal analysis which allows to determine the number of single nucleotide 
variations (SNVs) on single cell-derived DNA by whole exome sequencing (WES). 
We will compare numbers of SNVs in HSCs from animals with the following different 
HSC challenges: A) HSCs in steady state (6 months repetitive PBS injection), B) 
HSCs exposed to chronic inflammation (one injection every months for 6 months), C) 
HSCs that have been maximally expanded by 3 rounds of serial transplantation, D) 
aged HSCs (2 years old), E) HSCs that are driven into cell cycle through 
thrombopoietin receptor (c-Mpl) agonist treatment (weekly injection over 2 month and 
2 month recovery)29 and F) HSC that already carry a genetic mutation (JAK2-V617F) 
which is known to be a driver mutation for myeloproliferative neoplasms 141. These 
and other studies will allow to experimentally test the effect of inflammation and 
inflammation induced proliferation on the occurrence of relevant, possibly HSC to LIC 
transforming events. 
 
Hematopoietic stem and progenitor cells are maintained in the BM niche, which is 
very well characterized in mouse. However, little is known about the human BM niche 
and the interactions of HSCs with its environment. In the recent years, several 
studies developed different tissue engineering protocols, that are based on the ability 
of human MSCs to undergo endochondral ossification and develop a bone-like 
structure in vivo (reviewed in 55). In order to mimic a morphological and functional 
human BM niche, we took a developmental tissue engineering approach that allows 
to ex vivo generate a human cartilage template with human adult BM-derived MSCs, 
and to in vivo develop human bone organs (thereafter called “ossicles”) through 
endochondral ossification99. After implantation, human MSC-derived ossicles 
developed a vascular network and a mature trabecular bone-like structure. Flow-
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cytometric analysis at 2-month post CB transplantation showed comparable 
development of human hematopoiesis with phenotypic HSCs in the human ossicles 
compared to mouse BM. Myeloid-colony forming unit (CFU) assays and serial 
transplantation showed a significantly higher frequency of hematopoietic stem and 
progenitor cells maintained in human ossicles than in mouse BM. This suggests that 
human ossicles can serve as niche to support human hematopoiesis. Our study 
allows to study human HSCs in an environment that mimics more closely the human 
BM because of the in vitro endochondral differentiation before implantation. In 
contrast most of the studies directly implant undifferentiated MSC into mice and 
therefore cannot control their differentiation. The fact that we found immature and 
mature hematopoietic cells within the ossicle suggests a robust differentiation of 
human HSPCs within the human environment. The functional assays suggest that 
the human ossicle might have a local cytokine milieu that is closer to physiological 
conditions of human bone marrow, as they give rise to more functional HSPCs. 
These functional assays are not very well studied in the published ossicle models101 
as most of them were designed to increase human engraftment but not model a 
human BM niche. Several xenotransplantation models have been reported to 
improve engraftment of human HSCs by modifying human cytokines within immun-
compromised mouse models134,142-144 or co-transplantation of MSCs with HSPCs145 
or transplantation of engineered bioscaffolds103. The origin of the different ossicle 
niche cells still have to be investigated. One can assume that the osteogenic, 
adipogenic and stroma cells originate from the human donor MSCs while the 
endothelial cells as well as some hematopoietic cells are recruited from the recipient 
mouse. The engineering of a heterotrophic human BM niche that is transplantable 
and genetically re-engineerable will serve as a platform that allows to study 
physiology and pathophysiology of healthy and diseased human hematopoiesis in 
their optimized environment in vivo. However, the ossicle models in other recent 
studies do not mimic the morphological and functional features of the human 
niche100-102,146. Therefore, it might be difficult to translate these preclinical findings 
from bench to bedside. In contrast our studies might suggest a better model to 
predict results in medicine because of the higher similarity of the human ossicle to a 
human BM niche.  
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CONCLUSIONS 
 
 
1. During Inflammation, direct TLR4 activation induces HSC cycling and impairs 
their competitive repopulating ability. 
 
2. TLR4-signaling in HSCs is not MyD88 but TRIF-dependent and leads to 
activation of p38α and generation of ROS. 
 
3. Inhibition of TLR4-TRIF-ROS-p38 signalling prevents LPS-induced HSC 
dysfunction. 
 
4. Continuous TLR4-stimulation might lead to DNA damage in HSCs. 
 
5. BM-derived human MSCs can form a hematopoietic niche with human 
hematopoiesis (engineered ossicle). 
 
6. Functional human HSPCs are maintained within the human engineered bone 
organ in vivo. 
 
7. The human hematopoietic ossicle niche is re-engineerable, serving as a 
platform to study normal and malignant human hematopoiesis in vivo.  
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